Potent and selective human neuronal nitric oxide synthase inhibitors

Aminoquinoline-based compounds with specific structural features address the challenges of selective nNOS inhibition and BBB permeability, providing a potent therapeutic option for neurodegenerative disorders with minimal off-target effects.

WO2026236715A1PCT designated stage Publication Date: 2026-11-12NORTHWESTERN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027463
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current nNOS inhibitors face challenges in maintaining physiological NO signaling, ensuring selective targeting of nNOS while minimizing off-target effects and toxicity, and overcoming the blood-brain barrier for effective delivery in treating neurodegenerative disorders.

Method used

Development of aminoquinoline-based compounds with specific structural features that exhibit high potency, selectivity for nNOS over other NOS isoforms, and permeability across the blood-brain barrier, minimizing off-target effects and toxicity.

Benefits of technology

The compounds demonstrate potent inhibition of nNOS with high isoform selectivity and BBB permeability, offering a therapeutic approach for neurodegenerative disorders with reduced side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027463_12112026_PF_FP_ABST
    Figure US2026027463_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed are neuronal nitric oxide synthase (nNOS) inhibitors and methods of using the same in treating a disease or disorder associated with nNOS activity, such as a neurological disease or disorder, a cardiovascular disease or disorder, a cancer, or an inflammatory condition.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] POTENT AND SELECTIVE HUMAN NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims benefit of priority to U. S. Application Serial No. 63 / 802,413, filed May 8, 2025. The contents of which are incorporated by reference in its entirety.

[0003] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0004] This invention was made with government support under grant number GM131788 awarded by the National Institutes of Health. The government has certain rights in the invention.

[0005] BACKGROUND OF THE INVENTION

[0006] Neurodegenerative disorders are characterized by the progressive loss of neuronal function and structure, encompassing diseases such as Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis (ALS), among others. While neuronal damage also occurs in conditions like stroke, ischemia, cerebral palsy, and traumatic brain injury, the human and economic burden of neurodegeneration remains immense, with current treatments mainly limited to palliative care and symptom management. This underscores the significant need for novel, effective therapies to slow or prevent disease progression.

[0007] One promising therapeutic target is neuronal nitric oxide synthase (nNOS). Nitric oxide synthases (NOS) function as homodimers, with each monomer containing a reductase and an oxygenase domain. The reductase domain binds FAD, FMN, and NADPH, facilitating electron transfer, while the oxygenase domain contains heme and binds both L-arginine (substrate) and (6R)-5,6,7,8-tetrahydrobiopterin (H₄B) (cofactor). Calmodulin binding is involved in NOS activation, as it promotes inter-monomer electron flow, allowing the reductase domain of one monomer to supply electrons to the oxygenase domain of the other. This process enables the catalytic oxidation of L-arginine to L-citrulline, with the concomitant production of nitric oxide (NO), a signaling molecule involved in vasodilation, neurotransmission, and immune responses.

[0008] The nitric oxide (NO) radical is a cell signaling component for the smooth functioning of our central nervous system (CNS).1,2The role of NO in human physiology is to regulate neurotransmission,3immune response,4and vasodilation? In mammals, NO is produced by afamily of enzymes known as nitric oxide synthase (NOS) by a mechanism where L-arginine is converted to L-citrulline with a requirement of NADPH and molecular oxygen.6NOSs exist in three isoforms in humans: neuronal NOS (nNOS) which acts as a neurotransmitter,7-9endothelial NOS (eNOS) which regulates the blood pressure by relaxing muscles,10and inducible NOS (iNOS) which generates cytotoxic NO to kill pathogens and other unwanted microorganisms.11The production of NO by nNOS at physiological levels is involved in the healthy functioning of the brain,12but its overproduction leads to the formation of highly reactive species such as peroxynitrite (ONOO⁻).13-15The peroxynitrite causes nitration and nitrosylation of proteins, which leads to their misfolding and degradation.16Excess NO can also contribute to oxidative damage by reacting with superoxide to generate peroxynitrite, a highly reactive and damaging molecule. Indeed, elevated nNOS activity and NO levels have been implicated in or associated with numerous neurodegenerative disorders.

[0009] In the past few years, it has been shown that inhibition of nNOS was influential in treating neuronal damage in animal models.17,18However, this approach faces significant challenges, including maintaining physiological NO signaling involved in normal brain function and ensuring selective targeting of nNOS while minimizing off-target effects and toxicity. eNOS inhibition can lead to cardiovascular problems, whereas iNOS inhibition can result in immune defense failure.19,20Since the three NOS isoforms have similar active sites, designing inhibitors selective for nNOS over eNOS and iNOS for treating neurodegenerative disorders is quite challenging.21,22Another difficulty associated with a potential inhibitor is that it must be able to cross the bloodbrain barrier (BBB) for successful delivery to the CNS.23-27Because melanocytes in the skin are derived from the neural crest,28,29it has been found that nNOS inhibitors also inhibit the growth of melanoma.30,31

[0010] Our research group has been involved in developing selective nNOS inhibitors, revealing excellent potency with high isoform selectivity and BBB permeability.32-37Over the past decade, we have reported a series of aminoquinoline-based inhibitors. However, the previously reported compounds suffer from drawbacks such as poor permeability, low activity against human nNOS, compromised selectivity against other NOS isoforms (human eNOS and human iNOS), and off-target promiscuity.

[0011] There remains a need for nNOS inhibitors that possess desirable potency, selectivity, and / or permeability.BRIEF SUMMARY OF THE INVENTION

[0012] Disclosed herein are neuronal nitric oxide synthase (nNOS) inhibitors and methods of using the same in the treatment of diseases or disorders.

[0013] One aspect of the present disclosure provides a compound of formula (I), or a salt, hydrate, or solvate thereof,

[0014]

[0015] wherein

[0016] n is 0 or 2;

[0017] R1is halogen;

[0018] R2is -(CH2)m-NHRA, halogen, -OH, or -H;

[0019] R3is -OH, -H, -(CH2)m-NHRA; halogen, or -O-Ci-Cs-alkyl, wherein the -O-Ci-Ca-alkyl is optionally substituted with a Cs-Ce-cycloalkyl;

[0020] R4is -H or halogen;

[0021] R5is -H, halogen, or -OH;

[0022] m is 1 or 2; and

[0023] RAis H or Ci-Cs-alkyl;

[0024] with the proviso that one and only one of R2and R3is -(CH2)m-NHRA

[0025] One aspect of the present disclosure provides a salt of the compound of any one of claims 1-16 of formula (1-a).

[0026]

[0027] One aspect of the present disclosure provides a pharmaceutical composition comprising the compound disclosed herein, or a salt, hydrate, or solvate thereof, and a pharmaceutically acceptable excipient, carrier, or diluent.

[0028] One aspect of the present disclosure provides a method for treating a disease or disorder associated with neuronal nitric oxide synthase (nNOS) activity in a subject in need thereof, the method comprising administering an effective amount of the compound disclosed herein, or a salt, hydrate, or solvate thereof; or the pharmaceutical composition disclosed herein to the subject.

[0029] BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Non-limiting embodiments of the present invention will be described by way of example with reference to the accompanying figures, which are schematic and are not intended to be drawn to scale. In the figures, each identical or nearly identical component illustrated is typically represented by a single numeral. For purposes of clarity, not every component is labeled in every figure, nor is every component of each embodiment of the invention shown where illustration is not necessary to allow those of ordinary skill in the art to understand the invention.

[0031] Figure 1 shows the molecules synthesized in this study.

[0032] Figure 2 shows the binding mode of a representative 2-aminoquinoline derivative with the human neuronal nitric oxide synthase generated by the minimization of the crystal structure (PDB ID: 6PO7). For clear visualization, parts of the ligand other than the 2-aminoquinoline ring and most of the enzyme residues were omitted.

[0033] Figure 3 shows the theoretical surface electrostatic potential (ESP) of the ligand extracted from the minimized crystal structure (PDB ID: 6PO7) and its 6-halogen substituted derivatives from DFT calculation (B3LYP / 6-31G+**). (A) The atom numbering for the 2-aminoquinoline atoms participating in key interactions and calculated surface ESPs for each atom. The top and bottom of the box indicate the minimum ESP and the maximum ESP, respectively. The line in the box represents the mean ESP. (B) The relative surface ESP of each derivative compared to when X = H. Min, minimum surface ESP; Max, maximum surface ESP.

[0034] Figure 4 shows compound 7 bound to (A) hnNOS, (B) rnNOS, and (C) heNOS. In this and other structural figures, the major H-bonds that are key to the inhibitor binding are highlighted with dashed lines. The distances are labeled in A. The omit difference Polder density for the inhibitor is displayed at the 2.5-3.0 G contour level.Figure 5 shows compound 10 bound to (A) hnNOS, (B) rnNOS, and (C) heNOS.

[0035] Figure 6 shows compound 11 bound to (A) hnNOS, (B) rnNOS, and (C) heNOS.

[0036] Figure 7 shows compound 15 bound to (A) rnNOS and (B) heNOS.

[0037] Figure 8 shows the predicted binding mode of (A) 16, (B) 24, and (C, D) their 2D representations from docking results in the human neuronal nitric oxide synthase hnNOS- 10 structure (PDB ID: 9MYV). Various sticks represent binding site residues, cofactors, and each indicated ligand. Water molecules are shown in spheres. Various dotted lines indicate hydrogen bond, charge interaction, and π-interaction.

[0038] Figure 9 shows the molecular dynamics (MD) simulation results of 16 and 24 in hnNOS. (A, B) The binding modes of (A) 16, (B) 24, and their tail amino groups (in each box) in the representative frame of each MD trajectory. Various sticks represent binding site residues, cofactors, and compounds 16 and 24, respectively. Water molecules are shown in spheres. Various dotted lines indicate hydrogen bond (H-bond), charge interaction, and π-interaction. (C) Geometric measurements for tail part binding interactions. (D) Root-mean-square deviation (RMSD) of the ligand and distances of (E) H-bond with Tyr711, (F) charge interaction with heme propionate, and (G) H-bond with BH₄ cofactor during each MD simulation.

[0039] Figure 10 shows the effect of methyl substitution on the hydrated shell formation around the tail amino group of 24 during MD simulation in hnNOS. (A) The extracted representative conformation of 24 in the hnNOS binding site from MD trajectories and its atom numbering for dihedral angle measurement. (B) Dihedral angle measurement for C1-C2-N-C3 atoms during the simulation. (C) The radial distribution function, g(r), of water molecules around the amine nitrogen atom during MD simulation of each indicated molecule, r, distance from the amine nitrogen atom.

[0040] Figure 11 shows the superimposition of the predicted binding modes of 16 and 24 from docking results in the human neuronal nitric oxide synthase (hnNOS). Sticks represent binding site residues and cofactors. Water molecules are shown in spheres.

[0041] Figure 12 shows the partial ligand root-mean-square deviation (RMSD) during molecular dynamics (MD) simulation of 16 and 24 in the human neuronal nitric oxide synthase (hnNOS).

[0042] Figure 13 shows the representative binding mode of 16 around 73 ns of the simulation in the human neuronal nitric oxide synthase (hnNOS). Various sticks represent binding site residues, cofactors, and 16. Water molecules are shown in spheres. Various dotted lines indicate hydrogen bond, charge interaction, and π-interaction.Figure 14 shows (A, B) The protein-ligand complex energy from the molecular dynamics (MD) simulation of each indicated molecule in the human neuronal nitric oxide synthase (hnNOS) and (C) the corresponding binding free energy (ΔGbind) calculation results using molecular mechanics with generalized Born and surface area (MM / GBSA). The cross marks indicate the time points of sampled frames for calculation.

[0043] Figure 15 shows the microsolvation models of (A) 16 and (B) 24 in the human neuronal nitric oxide synthase (hnNOS) were used for binding free energy calculation.

[0044] DETAILED DESCRIPTION OF THE INVENTION

[0045] Disclosed herein are compounds and derivative thereof for use as neuronal nitric oxide synthase (nNOS) inhibitors. The compounds and compositions disclosed herein may be used in methods of treating diseases or disorders, such as neurological diseases or disorders, cardiovascular diseases or disorders, cell proliferative diseases or disorders (e.g., cancer), or inflammatory conditions.

[0046] Chemical Entities

[0047] The term "alkyl" refers to a straight-chain, branched, or cyclized alkyl radical in all of its isomeric forms, such as a straight or branched group of 1-12, 1-10, or 1-6 carbon atoms, referred to herein as Ci-Ci2-alkyl, Ci-Cio-alkyl, and Ci-Ce-alkyl, respectively.

[0048] The term "alkylene" refers to a diradical of straight-chain or branched alkyl group (e.g., a diradical of straight-chain or branched C1-C12 alkyl group). Exemplary alkylene groups include, but are not limited to -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH(CH3)CH2-, -CH2CH(CH3)CH2-, -CH(CH2CH3)CH2-, and the like.

[0049] The term "alkenyl" refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond, such as a straight or branched group of 2-12, 2-10, or 2-6 carbon atoms, referred to herein as C2-Ci2-alkenyl, C2-Cio-alkenyl, and C2-Cs-alkenyl, respectively.

[0050] The terms "alkoxy" or "alkoxyl" refers to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxy groups include methoxy, ethoxy, tertbutoxy and the like.

[0051] The term "cycloalkyl" refers to a monovalent saturated or partially saturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons,referred to herein, e.g., as " C4-s-cycloalkyl," derived from a cycloalkane. Unless specified otherwise, the cycloalkyl group is not substituted, i.e., it is unsubstituted.

[0052] The term "heterocycloalkyl" (or "heterocyclyl") refers to a monovalent saturated or partially saturated cyclic, bicyclic, or bridged cyclic hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons in which at least one carbon of the cycloalkane is replaced with a heteroatom such as, for example, N, O, and / or S.

[0053] The term "halo" or “halogen” refer to a halogen atom or halogen radical (e.g., -F, -Cl, -Br, or -I).

[0054] The term "haloalkyl" refers to an alkyl group that is substituted with at least one halogen. For example, -CH2F, -CHF2, -CF3, -CH2CF3, -CF2CF3, and the like.

[0055] The term "cyano" refers to -CN.

[0056] The term "aryl" refers to a carbocyclic aromatic group. The term "aryl" includes monocyclic ring systems, and polycyclic ring systems having two or more carbocyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is aromatic and, e.g., the other ring(s) may be cycloalkyls, cycloalkenyls, cycloalkynyls, and / or aryls. Unless specified otherwise, the aryl ring is unsubstituted. In certain embodiments, the aryl group is a 6-10 membered ring structure. Representative aryl groups include phenyl, naphthyl, anthracenyl, 1,3 -benzodi oxolyl and the like.

[0057] The substituents on the aryl (e.g., phenyl) rings in the compounds of the disclosure may be at ortho-, meta-, or para- positions.

[0058] The term "heteroaryl" refers to an aromatic 5- to 10-membered ring structure, alternatively 6- to 10-membered rings, whose ring structures include one to four heteroatoms, such as nitrogen, oxygen, and sulfur. The number of ring atoms in the heteroaryl group can be specified using Cx-Cx nomenclature where x is an integer specifying the number of ring atoms. For example, a C3-C7 heteroaryl group refers to an aromatic 3- to 7-membered ring structure containing one to four heteroatoms, such as nitrogen, oxygen, and sulfur. The term "heteroaryl" includes monocyclic ring systems, and polycyclic ring systems having two or more heterocyclic rings in which two or more carbon or heteroatom are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is a heterocyclic aromatic group and, e.g., the other ring(s) may be cycloalkyls, cycloalkenyls, cycloalkynyls, and / or aryls. Representative heteroaryl groups include pyridinyl, quinolinyl, furanyl, thionyl, indolyl, and the like.The term “optionally substituted” refers to zero, one or more carbon atoms in the group being independently substituted with one or more functional groups described herein.

[0059] The compounds of the disclosure may contain one or more chiral centers and / or double bonds and, therefore, exist as stereoisomers, such as geometric isomers, enantiomers or diastereomers. The term "stereoisomers" when used herein consist of all geometric isomers, enantiomers or diastereomers. These compounds may be designated by the symbols "?" or " S," or "+" or depending on the configuration of substituents around the stereogenic carbon atom and or the optical rotation observed. The present invention encompasses various stereo isomers of these compounds and mixtures thereof. Stereoisomers include enantiomers and diastereomers. Mixtures of enantiomers or diastereomers may be designated (±)" in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly. It is understood that graphical depictions of chemical structures, e g., generic chemical structures, encompass all stereoisomeric forms of the specified compounds, unless indicated otherwise. Also contemplated herein are compositions comprising, consisting essentially of, or consisting of an enantiopure compound, which composition may comprise, consist essentially of, or consist of at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of a single enantiomer of a given compound (e.g, at least about 99% of an R enantiomer of a given compound).

[0060] As used herein, "salt" refers to acid addition salts and basic addition salts. It may also refer to those salts that may be prepared in situ during the final isolation and purification of the compounds of the invention.

[0061] Examples of acid addition salts include, but are not limited to acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, di gluconate, glycerophosphate, hemi sulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isothionate), lactate, malate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmitate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, / ?-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups may be quatemized with such agents as lower alkyl halides such as, but not limited to, methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as, but not limited to, decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides like benzyl and phenethylbromides and others. Water or oil-soluble or dispersible products are thereby obtained. Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid and such organic acids as acetic acid, fumaric acid, maleic acid, 4-methylbenzenesulfonic acid, succinic acid, and citric acid.

[0062] Basic addition salts may be prepared in situ during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as, but not limited to, the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine. Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as, but not limited to, lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine and the like. Other examples of organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine and the like.

[0063] Compounds described herein may exist in unsolvated as well as solvated forms, including hydrated forms, such as hemi-hydrates. In general, the solvated forms, with pharmaceutically acceptable solvents such as water and ethanol among others are equivalent to the unsolvated forms for the purposes of the disclosure.

[0064] Compounds

[0065] One aspect of the present disclosure provides a compound of formula (I), or a salt, hydrate, or solvate thereof, such as a pharmaceutically acceptable salt, hydrate, or solvate thereof,

[0066]

[0067] R1is halogen;

[0068] R2is -(CH2)m-NHRA, halogen, -OH, or -H;

[0069] R3is -OH, -H, -(CH2)m-NHRA; halogen, or -O-C1-C5-alkyl, wherein the -O-C1-C5-alkyl is optionally substituted with a Cs-Ce-cycloalkyl;

[0070] R4is -H or halogen;

[0071] R3is -H, halogen, or -OH;

[0072] m is 1 or 2; and

[0073] RAis H or Ci-Cs-alkyl;

[0074] with the proviso that one and only one of R2and R3is -(CH2)m-NHRA.

[0075] In some embodiments, R1is -F.

[0076] In some embodiments, n is 0.

[0077] In some embodiments, R2is -CH2-NH2, -OH, -F, -H, -CH2-CH2-NH2, -CH2-NHMe, or -CH2-CH2-NMe. In some such embodiments, R2is -CH2-NH2.

[0078] In some embodiments, R3is -OH, -F, -O-CH2-cyclopropyl, -CH2-NH2, -H, -CH2-CH2-NH2, -CH2-NHMe, or -CH2-CH2-NMe. In some such embodiments, R3is -OH.

[0079] In some embodiments, R4is -H or -F.

[0080] In some embodiments, R3is -H, -F, or -OH.

[0081] In some embodiments, R4and R5are both -H.

[0082] In some embodiments, the compound is

[0083]

[0084]

[0085]

[0086] In some embodiments, the compound is

[0087]

[0088] The disclosed compounds may be formulated as pharmaceutical compositions comprising any of the compounds disclosed herein and a pharmaceutically acceptable excipient, carrier, or diluent.

[0089] The disclosed compounds and compositions comprising the same may exhibit one or more biological activities. In some embodiments, the disclosed compounds inhibit the activity of neuronal nitric oxide synthase (nNOS). The NOS inhibitory activity of the compounds disclosed herein may be measured using a hemoglobin (Hb) NO capture assay. In some embodiments, the disclosed compounds have an inhibition constant (Ki) for human nNOS which is less than about 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 1 nM, 0.5 nM, 0.1 nM or lower. In some embodiments, the disclosed compounds have an inhibition constant (Ki) for human nNOS that is down to 0.001 nM. The inhibition constants (Ki) may be calculated from the ICso values of the dose-response curves using the Cheng-Prusoff equation, according to methods described herein. Concentration ranges also are contemplated herein, for example, a concentration range bounded by end-point concentrations selected from 100 nM, 90 nM, 80 nM,70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 1 nM, 0.5 nM, 0.1 nM, and 0.001 nM.

[0090] In some embodiments, the disclosed compound adopts a similar binding mode to rnNOS (rat) and hnNOS (human). In some embodiments, the ratio of the Ki values of the inhibitors for human and rat nNOS (the hn / rn ratio) is from about 0.5 to about 1.8, from about 0.6 to about 1.5, from about 0.7 to about 1.4, from about 0.8 to about 1.3, from about 0.9 to about 1.2, or about 1.0.

[0091] In some embodiments, the disclosed compound is selective for human nNOS over human inducible NOS (iNOS). The isoform selectivity is determined by comparing the values of human nNOS with human iNOS. In some embodiments, the disclosed compounds exhibit a selectivity for human nNOS over human iNOS (hn / hi) which is at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, or higher. In some embodiments, the disclosed compounds exhibit a selectivity for human nNOS over human iNOS (hn / hi) that is up to 5,000. In some embodiments, the NOS inhibited by the disclosed compounds is a neuronal NOS which is inhibited selectively versus iNOS.

[0092] In some embodiments, the disclosed compound is selective for human nNOS over human endothelial NOS (eNOS). The isoform selectivity is determined by comparing the Ki values of human nNOS with human eNOS. In some embodiments, the disclosed compounds exhibit a selectivity for human nNOS over human eNOS (hn / he) which is at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, or higher. In some embodiments, the disclosed compounds exhibit a selectivity for human nNOS over human eNOS (hn / he) that is up to 3,000. In some embodiments, the NOS inhibited by the disclosed compounds is a neuronal NOS which is inhibited selectively versus eNOS.

[0093] In some embodiments, the disclosed compound with selectivity for human nNOS over human iNOS and / or human eNOS shows fewer side effects associated with inhibiting the eNOS and / or iNOS isoforms, compared to a reference compound that exhibits less selectivity for human nNOS over human iNOS and / or human eNOS. Possible side effects include, but are not limited to, cardiovascular side effects due to eNOS inhibition and immune suppression from iNOS inhibition.The disclosed NOS inhibitors may penetrate the blood-brain barrier (BBB). An effective permeability (Pe) greater than 4.0 × 10⁻⁶ cm s⁻¹ may be considered to indicate good BBB penetration and is classified as “CNS (+)”.

[0094] In some embodiments, the disclosed compound is classified as “CNS (+)”. In some embodiments, the disclosed compound exhibits an effective permeability (Pe) for the blood brain barrier of at least about 4.0 x 10‘6cm / s, 5.0 x 10‘6cm / s, 6.0 x 10‘6cm / s, 7.0 x 10‘6cm / s, 8.0 x 10'6cm / s, 9.0 x 10'6cm / s, 10.0 x 10'6cm / s, 11.0 x 10'6cm / s, 12.0 x 10'6cm / s, 13.0 x 10'6cm / s, 14.0 x 10'6cm / s, 15.0 x 10’6cm / s, 16.0 x 10'6cm / s, 17.0 x 10’6cm / s, 18.0 x 10'6cm / s, 19.0 x 10'6cm / s, or 20.0 x 10’6cm / s. In some embodiments, the disclosed compound exhibits an effective permeability (Pe) for the blood brain barrier that is up to about 30.0 x 10'6cm / s. In some embodiments, the blood-brain barrier penetration may be estimated using the PAMPA-BBB assay, according to methods described herein.

[0095] In some embodiments, the disclosed compound may achieve enhanced pharmacokinetic properties and / or improved metabolic stability, compared to a reference compound without any substitution (e.g., a fluoro-substitution) at the 6-position (i.e., Reposition) of the quinoline ring.

[0096] Another aspect of the present disclosure provides a salt of the compound disclosed herein of formula (I-a).

[0097]

[0098] Pharmaceutical Compositions

[0099] Another aspect of the present disclosure provides a pharmaceutical composition comprising the compound disclosed herein, or a salt, hydrate, or solvate thereof, and a pharmaceutically acceptable excipient, carrier, or diluent.

[0100] The compounds employed in the compositions and methods disclosed herein may be administered as pharmaceutical compositions and, therefore, pharmaceutical compositions incorporating the compounds are considered to be embodiments of the compositions disclosed herein. Such compositions may take any physical form which is pharmaceutically acceptable;illustratively, they can be orally administered pharmaceutical compositions. Such pharmaceutical compositions contain an effective amount of a disclosed compound, which effective amount is related to the daily dose of the compound to be administered. Each dosage unit may contain the daily dose of a given compound or each dosage unit may contain a fraction of the daily dose, such as one-half or one-third of the dose. The amount of each compound to be contained in each dosage unit can depend, in part, on the identity of the particular compound chosen for the therapy and other factors, such as the indication for which it is given. The pharmaceutical compositions disclosed herein may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing well known procedures.

[0101] In some embodiments, the compounds disclosed herein may be formulated as pharmaceutical compositions that include: (a) a therapeutically effective amount of one or more compounds as disclosed herein; and (b) one or more pharmaceutically acceptable carriers, excipients, or diluents. The pharmaceutical composition may include the compound in a range of about 0.1 to 2000 mg (preferably about 0.5 to 500 mg, and more preferably about 1 to 100 mg). The pharmaceutical composition may be administered to provide the compound at a daily dose of about 0.1 to about 1000 mg / kg body weight (preferably about 0.5 to about 500 mg / kg body weight, more preferably about 50 to about 100 mg / kg body weight). In some embodiments, after the pharmaceutical composition is administered to a subject (e.g., after about 1, 2, 3, 4, 5, or 6 hours post-administration), the concentration of the compound at the site of action may be within a concentration range bounded by end-points selected from 0.001 nM, 0.005 nM, 0.01 nM, 0.5 nM, 0.1 nM, 1.0 nM, 10 nM, and 100 nM (e.g., 0.1 nM - 1.0 nM).

[0102] It is understood by those skilled in the art that dosage amount will vary with the activity of a particular inhibitor compound, disease state, route of administration, duration of treatment, and like factors well-known in the medical and pharmaceutical arts. In general, a suitable dose will be an amount which is the lowest dose effective to produce a therapeutic or prophylactic effect. If desired, an effective dose of such a compound, pharmaceutically acceptable salt thereof, or related composition may be administered in two or more sub-doses, administered separately over an appropriate period of time.

[0103] The compounds for use according to the methods of disclosed herein may be administered as a single compound or a combination of compounds. For example, a compound that inhibits neuronal nitric oxide synthase may be administered as a single compound or in combination withanother compound that inhibits neuronal nitric oxide synthase or that has a different pharmacological activity. In some embodiments, one or more additional therapeutic agents may be administered with the disclosed compounds or with pharmaceutical compositions comprising the disclosed compounds, where the additional therapeutic agent is administered prior to, concurrently with, or after administering the disclosed compounds or the pharmaceutical compositions comprising the disclosed compounds. In some embodiments, the disclosed pharmaceutical composition is formulated to comprise the disclosed compounds and further to comprise one or more additional therapeutic agents, for example, one or more additional therapeutic agents for treating diseases and disorders.

[0104] As indicated above, pharmaceutically acceptable salts of the compounds are contemplated and also may be utilized in the disclosed methods. The term “pharmaceutically acceptable salt” as used herein, refers to salts of the compounds, which are substantially non-toxic to living organisms. Typical pharmaceutically acceptable salts include those salts prepared by reaction of the compounds as disclosed herein with a pharmaceutically acceptable mineral or organic acid or an organic or inorganic base. Such salts are known as acid addition and base addition salts. It will be appreciated by the skilled reader that most or all of the compounds as disclosed herein are capable of forming salts and that the salt forms of pharmaceuticals are commonly used, often because they are more readily crystallized and purified than are the free acids or bases. In some embodiments, HC1 salts of the disclosed compounds are provided.

[0105] Acids commonly employed to form acid addition salts may include inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic, methanesulfonic acid, oxalic acid, p-bromophenyl sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like. Examples of suitable pharmaceutically acceptable salts may include the sulfate, pyrosulfate, bisulfate, sulfite, bisulfate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, hydrochloride, dihydrochloride, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleat-, butyne-,1,4-dioate, hexyne-l,6-dioate, benzoate, chlorobenzoate, methylbenzoate, hydroxybenzoate, methoxybenzoate, phthalate, xylenesulfonate, phenyl acetate, phenylpropionate, phenylbutyrate, citrate, lactate, a-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate,naphthalene-1 -sulfonate, naphthalene-2-sulfonate, mandelate, and the like. In some embodiments, the disclosed compound forms an acid addition salt with dihydrochloride.

[0106] Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Bases useful in preparing such salts include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like.

[0107] The particular counter-ion forming a part of any salt of a compound disclosed herein may not be critical to the activity of the compound, so long as the salt as a whole is pharmacologically acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole. Undesired qualities may include undesirably solubility or toxicity.

[0108] Pharmaceutically acceptable esters and amides of the compounds can also be employed in the compositions and methods disclosed herein. Examples of suitable esters include alkyl, aryl, and aralkyl esters, such as methyl esters, ethyl esters, propyl esters, dodecyl esters, benzyl esters, and the like. Examples of suitable amides include unsubstituted amides, monosubstituted amides, and disubstituted amides, such as methyl amide, dimethyl amide, methyl ethyl amide, and the like.

[0109] In addition, the methods disclosed herein may be practiced using solvate forms of the compounds or salts, esters, and / or amides, thereof. Solvate forms may include ethanol solvates, hydrates, and the like.

[0110] Compositions can be formulated in a unit dosage form, each dosage containing from about 1 to about 500 mg of each compound individually or in a single unit dosage form, such as from about 5 to about 300 mg, from about 10 to about 100 mg, and / or about 25 mg. The term “unit dosage form” refers to a physically discrete unit suitable as unitary dosages for a patient, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier, diluent, or excipient.

[0111] The pharmaceutical composition may include the compound in a range of about 0.1 to 2000 mg. In some embodiments, the pharmaceutical composition may include the compound in a range of from about 0.5 to 500 mg. In some embodiments, the pharmaceutical composition may include the compound in a range of from about 1 to 100 mg. The pharmaceutical composition may be administered to provide the compound at a daily dose of about 0.1 to about 1000 mg / kg body weight. In some embodiments, the pharmaceutical composition may be administered to providethe compound at a daily dose of about 0.5 to about 500 mg / kg body weight. In some embodiments, the pharmaceutical composition may be administered to provide the compound at a daily dose of about 50 to about 100 mg / kg body weight. A typical daily dose may contain from about 0.01 mg / kg to about 100 mg / kg (such as from about 0.05 mg / kg to about 50 mg / kg and / or from about 0.1 mg / kg to about 25 mg / kg) of each compound used in the present method of treatment. In some embodiments, after the pharmaceutical composition is administered to a subject (e.g., after about 1, 2, 3, 4, 5, or 6 hours post-administration), the concentration of the compound at the site of action may be within a concentration range bounded by end-points selected from 0.001 nM, 0.005 nM, 0.01 nM, 0.5 nM, 0.1 nM, 1.0 nM, 10 nM, and 100 nM (e.g., 0.1 nM - 1.0 nM).

[0112] The compounds utilized in the methods disclosed herein may be formulated as a pharmaceutical composition that includes a carrier. For example, the carrier may be selected from the group consisting of proteins, carbohydrates, sugar, talc, magnesium stearate, cellulose, calcium carbonate, and starch-gelatin paste.

[0113] The compounds utilized in the methods disclosed herein may be formulated as a pharmaceutical composition that includes one or more binding agents, filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, and effervescent agents. Filling agents may include lactose monohydrate, lactose anhydrous, and various starches; examples of binding agents are various celluloses and crosslinked polyvinylpyrrolidone, microcrystalline cellulose, such as Avicel® PH101 and Avicel® PHI 02, microcrystalline cellulose, and silicified microcrystalline cellulose (ProSolv SMCC™). Suitable lubricants, including agents that act on the flowability of the powder to be compressed, may include colloidal silicon dioxide, such as Aerosil®200, talc, stearic acid, magnesium stearate, calcium stearate, and silica gel. Examples of sweeteners may include any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame. Examples of flavoring agents are Magnasweet® (trademark of MAFCO), bubble gum flavor, and fruit flavors, and the like. Examples of preservatives may include potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quaternary compounds such as benzalkonium chloride.

[0114] Suitable diluents may include pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and mixtures of any ofthe foregoing. Examples of diluents include microcrystalline cellulose, such as Avicel® PHI 01 and Avicel® PHI 02; lactose such as lactose monohydrate, lactose anhydrous, and Pharmatose® DCL21; dibasic calcium phosphate such as Emcompress®; mannitol; starch; sorbitol; sucrose; and glucose.

[0115] Suitable disintegrants include lightly crosslinked polyvinyl pyrrolidone, corn starch, potato starch, maize starch, and modified starches, croscarmellose sodium, cross-povidone, sodium starch glycolate, and mixtures thereof.

[0116] Examples of effervescent agents are effervescent couples such as an organic acid and a carbonate or bicarbonate. Suitable organic acids include, for example, citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts. Suitable carbonates and bicarbonates include, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate. Alternatively, only the sodium bicarbonate component of the effervescent couple may be present.

[0117] The compounds utilized in the methods disclosed herein may be administered in conventional dosage forms prepared by combining the active ingredient with standard pharmaceutical carriers or diluents according to conventional procedures well known in the art. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.

[0118] Pharmaceutical compositions comprising the compounds may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route. Such formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).

[0119] Pharmaceutical compositions adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or nonaqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

[0120] Pharmaceutical compositions adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for aprolonged period of time. For example, the active ingredient may be delivered from the patch by iontophoresis.

[0121] Pharmaceutical compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, impregnated dressings, sprays, aerosols or oils and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams.

[0122] For applications to the eye or other external tissues, for example the mouth and skin, the pharmaceutical compositions are in some embodiments applied as a topical ointment or cream. When formulated in an ointment, the compound may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the compound may be formulated in a cream with an oil-in-water cream base or a water-in-oil base. Pharmaceutical compositions adapted for topical administration to the eye include eye drops where the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.

[0123] Pharmaceutical compositions adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.

[0124] Pharmaceutical compositions adapted for rectal administration may be presented as suppositories or enemas.

[0125] Pharmaceutical compositions adapted for nasal administration where the carrier is a solid include a coarse powder having a particle size (e.g., in the range 20 to 500 microns) which is administered in the manner in which snuff is taken (i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose). Suitable formulations where the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.

[0126] Pharmaceutical compositions adapted for administration by inhalation include fine particle dusts or mists which may be generated by means of various types of metered dose pressurized aerosols, nebulizers or insufflators.

[0127] Pharmaceutical compositions adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

[0128] Pharmaceutical compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueousand non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.

[0129] Oral administration is an illustrative route of administering the compounds employed in the compositions and methods disclosed herein. Other illustrative routes of administration include transdermal, percutaneous, intravenous, intramuscular, intranasal, buccal, intrathecal, intracerebral, or intrarectal routes. The route of administration may be varied in any way, limited by the physical properties of the compounds being employed and the convenience of the subject and the caregiver.

[0130] Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fdlers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavoring or coloring agents.

[0131] Methods of preparing pharmaceutical formulations or compositions include the step of bringing a disclosed compound into association with a carrier and, optionally, one or more additional adjuvants or ingredients. For example, standard pharmaceutical formulation techniquescan be employed, such as those described in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA.

[0132] Regardless of composition or formulation, those skilled in the art will recognize various avenues for medicament administration, together with corresponding factors and parameters to be considered in rendering such a medicament suitable for administration.

[0133] As one skilled in the art will appreciate, suitable formulations include those that are suitable for more than one route of administration. For example, the formulation can be one that is suitable for both intrathecal and intracerebral administration. Alternatively, suitable formulations include those that are suitable for only one route of administration as well as those that are suitable for one or more routes of administration, but not suitable for one or more other routes of administration. For example, the formulation can be one that is suitable for oral, transdermal, percutaneous, intravenous, intramuscular, intranasal, buccal, and / or intrathecal administration but not suitable for intracerebral administration.

[0134] Methods

[0135] The disclosed compounds and pharmaceutical compositions comprising the disclosed compounds or a salt, hydrate, or solvate thereof may be administered in methods of treating a disease or a disorder in a subject in need thereof, such as in methods of treating a disease or disorder associated with neuronal nitric oxide synthase activity.

[0136] Another aspect of the present disclosure provides a method of treating a disease or disorder associated with neuronal nitric oxide synthase (nNOS) activity in a subject in need thereof, the method comprising administering an effective amount of the compound disclosed herein, or a salt, hydrate, or solvate thereof; or the pharmaceutical composition disclosed herein to the subject.

[0137] As used herein, the terms “treating” or “to treat” each mean to alleviate symptoms, eliminate the causation of resultant symptoms either on a temporary or permanent basis, and / or to prevent or slow the appearance or to reverse the progression or severity of resultant symptoms of the named disease or disorder. As such, the methods disclosed herein encompass both therapeutic and prophylactic administration.

[0138] A “subject in need thereof’ as utilized herein refers to a subject in need of prevention and / or treatment for a disease or disorder associated with nNOS activity. The term “subject” may be used interchangeably with the terms “individual” and “patient” and includes human and non-human mammalian subjects. In some embodiments, the treated subject may be a mammalian subject.Although the methods disclosed herein are particularly intended for the treatment of humans, other mammals are included. By way of non-limiting examples, mammalian subjects include monkeys, equines, cattle, canines, felines, mice, rats and pigs.

[0139] As used herein, the term "disorder" refers to a condition in which there is a disturbance of normal functioning. A "disease" is any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. Sometimes the term is used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function, while in other contexts these may be considered distinguishable categories. It should be noted that the terms "disease", "disorder", "condition" and "illness", are equally used herein.

[0140] In some embodiments, the disease or disorder is a neurological disease or disorder, such as a neurodegenerative disease or disorder. Neurological diseases or disorders include, but are not limited to, Alzheimer's disease (AD), migraine, epilepsy, chronic pain, stroke, autism spectrum disorder, Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).

[0141] In some embodiments, the disease or disorder is a cell proliferative disease or disorder, such as a cancer. Cancers include, but are not limited to, melanoma, breast, glioma, prostate, and lung cancer.

[0142] In some embodiments, the disease or disorder is a cardiovascular disease or disorder. Cardiovascular diseases or disorders include, but are not limited to, hypertension, heart failure, erectile dysfunction, and atherosclerosis.

[0143] In some embodiments, the disease or disorder is an inflammatory condition. Inflammatory conditions include, but are not limited to, arthritis, inflammatory bowel disease, and asthma.

[0144] In some embodiments, the disclosed method incurs no side effects, or fewer side effects, compared to a method that comprises administering an alternative compound. Possible side effects include, but are not limited to, cardiovascular side effects due to eNOS inhibition and immune suppression from iNOS inhibition.

[0145] In some embodiments of the disclosed treatment methods, the subject may be administered a dose of a compound as low as 1.25 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg, 27.5 mg, 30 mg, 32.5 mg, 35 mg, 37.5 mg, 40 mg, 42.5 mg, 45 mg, 47.5 mg, 50 mg, 52.5 mg, 55 mg, 57.5 mg, 60 mg, 62.5 mg, 65 mg, 67.5 mg, 70 mg, 72.5 mg, 75 mg,77.5 mg, 80 mg, 82.5 mg, 85 mg, 87.5 mg, 90 mg, 100 mg, 200 mg, 500 mg, 1000 mg, or 2000 mg once daily, twice daily, three times daily, four times daily, once weekly, twice weekly, or three times per week in order to treat the disease or disorder in the subject. In some embodiments, the subject may be administered a dose of a compound as high as 1.25 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg, 27.5 mg, 30 mg, 32.5 mg, 35 mg, 37.5 mg, 40 mg, 42.5 mg, 45 mg, 47.5 mg, 50 mg, 52.5 mg, 55 mg, 57.5 mg, 60 mg, 62.5 mg, 65 mg, 67.5 mg, 70 mg, 72.5 mg, 75 mg, 77.5 mg, 80 mg, 82.5 mg, 85 mg, 87.5 mg, 90 mg, 100 mg, 200 mg, 500 mg, 1000 mg, or 2000 mg, once daily, twice daily, three times daily, four times daily, once weekly, twice weekly, or three times per week in order to treat the disease or disorder in the subject. Minimal and / or maximal doses of the compounds may include doses falling within dose ranges having as end-points any of these disclosed doses (e.g, 2.5 mg - 200 mg).

[0146] In some embodiments of the disclosed treatment methods, a minimal dose level of a compound for achieving therapy in the disclosed methods of treatment may be at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1200, 1400, 1600, 1800, 1900, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 15000, or 20000 ng / kg body weight of the subject. In some embodiments, a maximal dose level of a compound for achieving therapy in the disclosed methods of treatment may not exceed about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1200, 1400, 1600, 1800, 1900, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 15000, or 20000 ng / kg body weight of the subject. Minimal and / or maximal dose levels of the compounds for achieving therapy in the disclosed methods of treatment may include dose levels falling within ranges having as end-points any of these disclosed dose levels (e.g., 500 - 2000 ng / kg body weight of the subject).

[0147] As used herein the term “effective amount” refers to the amount or dose of the compound or composition, upon single or multiple dose administration to the subject, which provides the desired effect in the subject under diagnosis or treatment. The disclosed methods may include administering an effective amount of the disclosed compounds (e.g, as present in a pharmaceutical composition) for treating a disease or disorder associated with neuronal nitric oxide synthase activity.

[0148] An effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of known techniques and by observing results obtained underanalogous circumstances. Tn determining the effective amount or dose of compound administered, a number of factors can be considered by the attending diagnostician, such as: the species of the subject; its size, age, and general health; the degree of involvement or the severity of the disease or disorder involved; the response of the individual subject; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.

[0149] The compounds and compositions disclosed herein may be administered in methods of treatment as known in the art. Accordingly, various such compounds and compositions can be administered in conjunction with such a method in any suitable way. For example, administration may comprise oral, intravenous, intraarterial, intramuscular, subcutaneous, intraperitoneal, parenteral, transdermal, intravaginal, intranasal, mucosal, sublingual, topical, rectal or subcutaneous administration, or any combination thereof.

[0150] Miscellaneous

[0151] Unless otherwise specified or indicated by context, the terms “a”, “an”, and “the” mean “one or more.” For example, “a molecule” should be interpreted to mean “one or more molecules.” As used herein, “about”, “approximately,” “substantially,” and “significantly” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which they are used. If there are uses of the term which are not clear to persons of ordinary skill in the art given the context in which it is used, “about” and “approximately” will mean plus or minus <10% of the particular term and “substantially” and “significantly” will mean plus or minus >10% of the particular term.

[0152] As used herein, the terms “include” and “including” have the same meaning as the terms “comprise” and “comprising.” The terms “comprise” and “comprising” should be interpreted as being “open” transitional terms that permit the inclusion of additional components further to those components recited in the claims. The terms “consist” and “consisting of’ should be interpreted as being “closed” transitional terms that do not permit the inclusion additional components other than the components recited in the claims. The term “consisting essentially of’ should be interpreted to be partially closed and allowing the inclusion only of additional components that do not fundamentally alter the nature of the claimed subject matter.

[0153] The phrase “such as” should be interpreted as “for example, including.” Moreover, the use of any and all exemplary language, including but not limited to “such as”, is intended merely tobetter illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed.

[0154] Furthermore, in those instances where a convention analogous to “at least one of A, B and C, etc.” is used, in general such a construction is intended in the sense of one having ordinary skill in the art would understand the convention (e.g., “a system having at least one of A, B and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together.). It will be further understood by those within the art that virtually any disjunctive word and / or phrase presenting two or more alternative terms, whether in the description or figures, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or ‘B or “A and B.” All language such as “up to,” “at least,” “greater than,” “less than,” and the like, include the number recited and refer to ranges which can subsequently be broken down into ranges and subranges. A range includes each individual member. Thus, for example, a group having 1-3 members refers to groups having 1, 2, or 3 members. Similarly, a group having 6 members refers to groups having 1, 2, 3, 4, 5, or 6 members, and so forth.

[0155] The modal verb “may” refers to the preferred use or selection of one or more options or choices among the several described embodiments or features contained within the same. Where no options or choices are disclosed regarding a particular embodiment or feature contained in the same, the modal verb “may” refers to an affirmative act regarding how to make or use and aspect of a described embodiment or feature contained in the same, or a definitive decision to use a specific skill regarding a described embodiment or feature contained in the same. In this latter context, the modal verb “may” has the same meaning and connotation as the auxiliary verb “can.” All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[0156] Aspects of this disclosure are described herein, including the best mode known to the inventors for carrying out the disclosure. Variations of those aspects can become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect a person having ordinary skill in the art to employ such variations as appropriate, and the inventors intend for the disclosure to be practiced otherwise than as specifically described herein. Accordingly, this disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the abovedescribed elements in all possible variations thereof is encompassed by the disclosure unless otherwise indicated herein or otherwise clearly contradicted by context.

[0157] EXAMPLES

[0158] Chemistry

[0159] Molecules synthesized in this study are shown in Figure 1.

[0160] The synthesis initially focused on 33 as the head part so that different linkers could be attached to it with various types of chains as the tail (Scheme 1). Commercially available 3-bromo-4-fluoroaniline (25) was refluxed with methyl acetoacetate, followed by its treatment with sulfuric acid, leading to intermediate 27. Compound 27 reacted with POCh producing 2-chloro derivative 29. Compound 29 underwent an addition-elimination reaction with 4-methoxybenzylamine in the presence of EtsN in / / -butanol under refluxing conditions to give 31, which was subsequently treated with TFA at 60 °C, providing the 2-amino derivative, which was di-Boc protected using Boc anhydride to give 33. Similarly, starting from commercially available 3-bromo-4-chloroaniline (26) and following the same sequence of reactions, we achieved 34.Scheme 1. Synthetic route to 33 and 34a

[0161]

[0162] aReagents and conditions: (a) i) methyl 3-oxobutanoate, KOH, toluene, 100 °C, 16 h; ii) H2SO4, 120 °C, 3 h; (b) POCI3, 120 °C - rt, 14 h; (c) 4-methoxybenzylamine, EtsN, / 7-BU4NI, n- butanol, 150 °C, 10 h; (d) i) TFA, 70 °C, 2 h; ii) (Boc)2O, DMAP, CH3CN, 70 °C.

[0163] The synthetic route to inhibitors 7 and 8 requires commercially available linker 35. Fluorosubstituted head molecule 33 was coupled with 35 to give Suzuki adduct 36 (Scheme 2). The nitrile functionality in 36 was reduced to the primary amine using a combination of NaBH4 and NiC12.6H2O, followed by in situ Boc protection to produce 38. Finally, treating Boc-protected amine derivatives 38 with 4 N HCl / l,4-di oxane gave 7. Similarly, coupling 34 and 35 and following the same sequence of reactions produced chi oro-substituted compound 8.

[0164] Scheme 2. Synthetic route to 7 and 8a

[0165]

[0166] aReagents and conditions: (a) Pd(dppf)Ch, B2(Pin)2, KO Ac, K2CO3, H2O, 1,4-di oxane, 130 °C, microwave; (b)NiC12.6H2O, NaBH4, Et3N, (Boc)2O, CH3OH, 25 °C, 2 h; (c) HCl / l,4-dioxane, 0 °C - 25 °C, 12 h.

[0167] Various linkers (41, 44, 45, 48, 49, 54, and 58) with polar chains were synthesized for inhibitors 9-24 and outlined in Scheme 3.

[0168] Scheme 3. Synthesis of 41, 44, 45, 48, 49, 54, and 58a

[0169]

[0170] aReagents and conditions: (a) C4H? Br, Et3N, CHCI3, 65 °C, 12 h; (b) MOMCl, Et3N, CHCI3, 65 °C, 12 h; (c) LiAlH4, THF, 0 °C, 30 min; (d) CBr4, PPh3, DCM, 25 °C, 12 h; (e) KCN, H-BU4NI, DCM: H2O (1: 1), 25 °C, 12 h; (f) BH3. SMe2, THF, 0 °C - 25 °C, 20 h.

[0171] The commercially available hydroxy-substituted benzonitrile (40) was subjected to O-alkylation using cyclopropyl methyl bromide and Et3N, producing 41 (Scheme 3). Similarly, (42, 43, 46, and 47) were subjected to (9-alkylation with MOMCl to give 44, 45, 48, and 49, respectively. The synthetic approach for linker 54 started from commercially available methyl 4-bromo-3-hydroxybenzoate (50), which undergoes O-alkylation with MOMCl to give 51. Ester 51was reduced to alcohol 52 using LiAlH4 and further transformed into bromide 53 via the Appel reaction. Compound 53 was converted to the corresponding nitrile (54) using KCN. In the same way, linker 58 was synthesized starting from commercially available carboxylic acid 55 by reducing it to alcohol 56 with BH3. Alcohol 56 was transformed into nitrile 58 via the same synthetic route as 52 was converted to 54 (Scheme 3).

[0172] The synthetic route to inhibitors 9-12 requires different linkers (44, 45, 54, and 58), and each was coupled with head molecule 33 following the same synthetic sequence as in Scheme 2, producing 9-12 (Scheme 4).

[0173] Scheme 4. Synthesis of 9-12a

[0174]

[0175]

[0176] “Reagents and conditions: (a) Pd(dppf)Ch, B2(Pin)2, KO Ac, K2CO3, H2O, 1,4-di oxane, 130 °C, microwave; (b) NiCl2.6H2O, NaBH4, Et3N, (Boc)2O, CH3OH, 25 °C, 2 h; (c) HCl / l,4-dioxane, 0 °C - 25 °C, 12 h.

[0177] Molecules 13 and 14 were synthesized with a two-carbon chain between the head and the linker to increase the flexibility of the molecule and the basicity of the 2-amino pyridine moiety. The synthesis was initiated from 58 by subjecting it to Sonogashira coupling with trimethyl silylacetylene to give 67 under microwave conditions (Scheme 5). The trimethyl silyl group in 67 was deprotected using K2CO3 at room temperature to give alkyne 68. Head molecule 33 was connected to alkyne 68 via Sonogashira coupling to give 69, which was further hydrogenated with H2, Pd / C, giving 70. The nitrile in 70 was reduced to a primary amine using NaBH4and NiCh.6H2O, followed by in situ Boc protection, producing 71, which was methylated using a combination of NaH and Mel, followed by acidolysis with HCl / l,4-dioxane to give 13.

[0178] Similarly, direct acidolysis of 71 gave 14.Scheme 5. Synthesis of 13 and 14a

[0179]

[0180] “Reagents and conditions: (a) ethynyltrimethylsilane, Pd(dppf)Cl2, Cui, Et3N, PPh3, 120 °C, CH3CN, microwave, 1 h; (b) K2CO3, MeOH, 25 °C, 2 h; (c) 33, Pd(dppf)Ch, Cui, Et3N, PPh3, 90 °C, CH3CN, microwave, 1 h; (d) H2, Pd / C, MeOH, 25 °C, 12 h; (e) NiCl2.6H2O, NaBH4, Et3N, (BOC)2O, CH3OH, 25 °C, 2 h; (f) i) NaH, Mel, THF 0 °C - 25 °C, 12 h; ii) HCl / l,4-di oxane, 25 °C, 12 h (g) HCl / l,4-di oxane, 25 °C, 12 h.

[0181] We also explored the meta- and c / ra-posi lions of the central phenyl ring. The 6-fluoro analogue of 5 was synthesized by coupling 33 with linker 41, giving 15 (Scheme 6) using the same sequence of reactions to make 9-12 (Scheme 4). The hydroxyl group at the 4-position of linker 44 was moved to the 2-position (48) and further transformed into 16.

[0182] Commercially available linker 72 was introduced to incorporate a fluorine at 2-position as a bioisostere that decreases the metabolism and increases the potency of the inhibitor.43Compound 17 was synthesized following the same sequence of reactions as in Scheme 4. The position of the aminomethyl group and hydroxyl or fluorine in 16 and 17, respectively, was interchanged to give 18 and 19 by coupling head 33 with the corresponding linkers 49 and 73, respectively (Scheme 6)Scheme 6. Synthesis of 15-19a

[0183]

[0184]

[0185] “Reagents and conditions: (a) Pd(dppf)Ch, B2(Pin)2, KO Ac, K2CO3, H2O, 1,4-di oxane, 130 °C, microwave; (b) NiCh.6H2O, NaBH4, Et3N, (Boc)2O, CH3OH, 25 °C, 2 h; (c) HCl / l,4-dioxane, 0 °C - 25 °C, 12 h.

[0186] A structural modification to the tail was made by methylation of the primary amine in 9-11, 15, and 16. The Boc-protected amine functionality (63-65, 79, and 80) was methylated using NaH and Mel, followed by hydrolysis to 20-24 (Scheme 7).Scheme 7. Synthesis of 20-24a

[0187]

[0188] aReagents and conditions: (a) i) NaH, Mel, THF 0 °C - 25 °C, 12 h; ii) HCl / l,4-di oxane, 25 °C, 12 h.

[0189] Results and Discussion

[0190] Surface Electrostatic Potential (ESP) analysis

[0191] The interaction between hnNOS and arginine, the natural substrate of NOS, has been well- established by available crystal structures44,45The reported 2-aminoquinoline nNOS inhibitors interact with the main chain carbonyl of Trp592 and interact with the side chain carboxylate of Glu597 in hnNOS through hydrogen bond and charge interactions (Figure 2), similar to arginine42To enhance the key interactions of 2-aminoquinoline derivatives, the surface electrostatic potential (ESP) of the 6-fluoro and 6-chloro derivative was calculated for each compound using quantum mechanical calculations with density functional theory (DFT). Upon performing DFT calculations at the B3LYP / 6-31G+** theory level, both fluorine and chlorine substitution at the 6-position increased the positive surface ESP around the hydrogen atoms participating in hydrogen bondsand charge interactions (Figure 3). The result suggested that 6-halogen substitution could enhance the binding affinity of 2-aminoquinoline derivatives in hnNOS.

[0192] However, in addition to hydrogen bonds and charge interactions with Trp592 and Glu597, the 2-aminoquinoline ring forms 7r-stacking with heme (Figure 2). Considering that the oxidation state of heme iron could change upon activation from the ferric resting stage to the peroxoferric species,46,47the 2-aminoquinoline ring has the potential to interact with the heme iron ion through a cation-7t interaction. Accurately predicting the impact of the 6-halogen group on the interaction between the 2-aminoquinoline and the heme by quantum mechanical calculation is challenging due to the complexity of the heme structure and its oxidation state, but it provides a rationale to proceed.

[0193] Biochemical activity of the nNOS inhibitors

[0194] A study of the surface electrostatic potential (ESP) indicated that the substitution of a halogen atom at the 6-position (in 7 and 8, Figure 1) enhances the binding affinity of 2-aminoquinoline derivatives in hnNOS (Figure 3). To determine which halogen substitution should be made at the 6-position of the aminoquinoline moiety, the potency and selectivity of 7 and 8 were determined using the NO hemoglobin (Hb) capture assay (see the Supplementary Information for details)48,49Of the two, fluoro substituted compound 7 was much more potent and selective than chloro- substituted compound 8 (Table 1).

[0195] With a fluoro- substituted compound 7 as a key molecule, we designed a few closely related compounds 9-24 (Figure 1) and assayed them against purified hnNOS. We investigated the effect of different electronic changes by various structure-based modifications. First, we employed a hydroxyl group at the or / Ao-position along with an aminoalkyl tail at the z«cZc / / / wzz-positions of the central phenyl ring attached as a linker (9-11). To enhance lipophilicity, difluoro-substituted phenyl rings (12-14) were also synthesized. We explored the o / VAo-position with the hydroxyl / fluoro substituents with a polar primary amine tail (15-19). The fluoro-substituted scaffolds in drug discovery provide more profound insights, positive outcomes on metabolic pathways, and enhanced potency.43At last, the SAR of the secondary amines (20-24) on various positions of the phenyl ring, along with a meta- or orz / v -positioned hydroxyl or O-alkyl group, were explored to analyze the steric and polar effects. Whenever possible, the crystal structures of these inhibitors bound to hnNOS, rnNOS, and heNOS were determined to provide the SAR information in detail.The potency and selectivity of the newly synthesized compounds (7-24) were assayed against purified human nNOS as a prescreen. The most potent compounds were further assayed against purified human eNOS, human iNOS, and rat nNOS to determine the isoform selectivity. The isoform selectivity is determined by the ratio of the K values of hnNOS over heNOS (hn / he) or over hiNOS (hn / hi). However, the ratio of hn / rn is useful to characterize the inhibitors for preclinical and clinical studies.

[0196] Table 1. Inhibition of NOS enzyme by synthesized compounds 7-24

[0197]

[0198] The compounds (7-24) were assayed for in vitro inhibition against four purified NOS isoforms: hnNOS, rnNOS, heNOS, and hiNOS, using known literature methods. Ki values were calculated from the ICso values of a dose-response curve using the Cheng-Prusoff equation. Allexperimental standard error values (for the log IC50) are less than 10%, and all correlation coefficients are good (r2> 0.87). Selectivity values are ratios of respective Ki values. N. T. = not tested, N. D. = not determined.

[0199] Surprisingly the di-HCl salts of all A-Me derivatives 20-24 were inactive compared to the corresponding primary amine derivatives (Table 1). Compounds with difluorophenyl central ring (12 and 14) were much poorer inhibitors of hnNOS than compounds 15-19.

[0200] Assessment of membrane permeability of the nNOS inhibitors

[0201] The most potent inhibitors (10, 11, and 15-19) from the NOS inhibition assay were further tested for their membrane permeability using the parallel artificial membrane permeability for the blood-brain barrier (PAMPA-BBB) assay. An effective permeability (Pe) greater than 4.0 * 10'6cm s1is considered to indicate good BBB penetration and is classified as “CNS (+)”.24>50>51inthis assay, we used porcine brain lipid as an artificial membrane for analyzing the passive permeability of the selected compounds. Two commercial drugs, theophylline and verapamil, were used as negative and positive control, respectively, during each permeability test of the selected NOS inhibitors (Table 2). Compound 15, a 6-fluoro substituted analogue of compound 5, displayed almost similar value with higher permeability ( e = 14.37 ± 2.09 x 10'6cm s'1).42Compounds 10 and 11 displayed the lowest permeability values among all the selected compounds presumably because of the hydroxyl group, and they are predicted not to be CNS permeable. However, 16 and 18 also have hydroxyl group substitution, but they are predicted to be CNS permeable. This may arise because their hydroxyl group can undergo intramolecular hydrogen bonding with the adjacent aminomethyl substituent. Intramolecular hydrogen bonding increases lipophilicity.52Compound 16 is much more permeable than 18, even though both can participate in intramolecular hydrogen bonding. The / / ra-hydroxyl group of 16 is in resonance with the nitrogen atom of the quinoline ring, thereby lowering the p / C of the hydroxyl group. This may allow for a more stable intramolecular hydrogen bond than 18, whose weta-hydroxyl group does not have that effect. Compound 17 has the largest Pc, greater than isomer 19 again because the polarity of the fluorine atom is decreased by a / / ra- resonance effect.

[0202] Table 2. Effective permeability (Pe) of commercial drugs and the synthesized nNOS inhibitors in the PAMPA-BBB assay

[0203]

[0204]

[0205] “Effective permeability (Pe) values from the literature.42

[0206] bAll assays were performed over 17 h at a concentration of 200 pM; see the Supporting Information for details.

[0207] CCNS (±) = likely high BBB permeation. CNS (-) = likely low BBB permeation. The “predictions” for the two literature-based compounds listed have been experimentally tested.

[0208] SAR studies with crystal structures for 7, 10, 11, and 15

[0209] 7 and 8 have a halogen (F and Cl) at the 6-position of the 2-aminoquinoline, respectively. The inhibitory activity assays indicated that 7 is more potent than 8. Consequently, we determined the structures of 7 bound to three NOS isoforms, as shown in Figure 4. 7 binds to the active site of all three NOSs with nitrogen atoms from its 2-aminoquinoline moiety H-bonded to the active site glutamate (Glu597 in hnNOS, Glu592 in rnNOS, and Glu361 in heNOS) and the backbone carbonyl group from a nearby Trp residue. The quinoline ring is more or less parallel to the heme plane with the 6-fluorine atom in a van der Waals distance (4.0 - 4.3 A) to a Met residue (Met575 in hnNOS, Met570 in rnNOS, and Met339 in heNOS) flanking the substrate binding pocket. The central phenyl ring sits on top of the heme propionates. The tail aminomethyl group points away from the pterin site water molecule in both hnNOS and rnNOS but displaces the water, making a H-bond with propionate A in the heNOS-7 structure. The electron density for the tail aminomethyl group in both hnNOS and rnNOS is weak, but it is clear that the pterin site water is not displaced. In both nNOS structures, there is a water molecule between the tail aminomethyl group of 7 and a nearby Asn residue bridging the H-bonding interactions. The almost identical binding mode of 7 in hnNOS and rnNOS structures agrees with its similar potency for both nNOSs.In addition to the 6-chloro substituted compound 8, we tested two other compounds with either an ethyl or a propyl group at the 6-position of the 2-aminoquinoline ring. While 8 shows weaker potency than 7, the other two compounds with bulkier 6-substituents did not bind to the NOS crystal preparation. Based on the known van der Waals contact from the 6-fluorine in the crystal structures (Figure 4), the bulkier substituents, Cl, ethyl, and propyl groups, would clash with the nearby Met residue. Therefore, 7 was used as the standard scaffold to develop the 2-aminoquinoline-based inhibitors further.

[0210] The next modification was the introduction of two substituents on the central phenyl ring at either ortho- and meta-positions (compound 9) or ortho- and / ?ara-positions (compounds 10 and 11). Compounds 10 and 11 showed much better potency than 9, so we obtained crystal structures for both. The binding mode of 10 was found to be quite similar in all three NOS structures (Figure 5). The / 7 / w-hydroxyl group fits in between the two propionates pointing downward; it can form a good H-bond with propionate D in both rnNOS and heNOS, but the bond distance is long in hnNOS. The tail aminomethyl group at the / z / z / -position makes a good H-bond with the pterin site water molecule in all three structures. Apparently, the aminomethyl group at the para-position in 10 makes it easier to interact with the pterin site water molecule than the meta-nmi nomethyl in 7. Based on the known structural information, the dual ortho- and me / a-substituents in 9 would have had to adopt an awkward position for the aminomethyl group to make any favorable interactions with the protein, which explains its poor potency.

[0211] When the aminomethyl group in 10 is changed to an aminoethyl in 11, it is long enough to form dual H-bonds to propionate A and BH4 in both hnNOS and rnNOS, as shown in Figures 6A and 6B. The strong H-bonds may account for the better affinity of 11 than 10 to hnNOS. However, the tail aminoethyl group of 11 can only make an H-bond with the pterin site water molecule in heNOS (Figure 6C). In heNOS-11, the loss of direct H-bonds with propionate A and BH4 in heNOS-10 might explain the poorer potency of 11 than 10. The central phenyl ring of 11 still sits in between the two propionates, with the oz7 / w-hydroxyl group pointing downward, making a H-bond with propionate D in all three structures. The gain in potency in hnNOS and loss of potency in heNOS reflect the better hn / he selectivity for 11.

[0212] When the difluorobenzene was introduced in 12-14, the potency with hnNOS worsened significantly (Table 1). Difluorobenzene was used in the 2-aminopyridine-based inhibitors with good success.33The difluorobenzene ring sits on top of the heme plane in structures of the 2-aminopyridine-based inhibitors. However, the bulkier 2-aminoquinoline compounds push the difluorobenzene ring onto the propionates, causing serious clashes.

[0213] Next, we attempted dual substituents at both the meta- and / / ra-positions of the phenyl ring in 15-19, with the primary aminomethyl group as one of the two substituents. As shown in Figure 7, the dual substituents on the phenyl ring of 15 cause the ring to rotate toward propionate D, forcing the latter into a downward conformation in both the rnNOS-15 and heNOS-15 structures. The meta-aminomethyl of 15 makes a H-bond with the pterin site water molecule in rnNOS. Still, the same aminomethyl group of 15 in heNOS directly displaces the pterin site water, forming H-bonds with both propionate A and BH4. This difference resulted from the interactions between the ( -alkyl tail and a hydrophobic residue in the two NOS isoforms. The bulkier Phel05 in heNOS makes tighter van der Waals contacts with the O-alkyl tail of 15, thereby pushing the aminomethyl group on the phenyl ring closer to propionate A for a H-bond and displacing the pterin site water molecule (Figure 7, panel B). Leu337 in rnNOS makes looser contacts with the O-alkyl tail of 15, which instead of displacing the pterin site water molecule, the aminomethyl group makes a H-bond with the water molecule (Figure 7, panel A).

[0214] The crystal structures of 15 bound to rnNOS and heNOS provide evidence that the dual meta- and / % / ra-substituents on the phenyl ring with a primary aminomethyl group fit in the NOS active site rather favorably, which agrees with the good potency of 15-19 for nNOS (Table 1).

[0215] However, methylation of the primary amine as in 20-24, diminished binding affinity for hnNOS by >62500 fold. To rationalize this unexpected result, we carried out molecular dynamics simulations as crystallography was impractical.

[0216] Binding analysis of 16 and 24 via molecular dynamics (MD) simulation

[0217] The binding modes of 16 and 24 were predicted by a docking study designed to investigate the effect of the methyl group on binding. Based on docking in the crystal structure of the hnNOS-10 complex (PDB ID: 9MYV), the binding mode of the two molecules was highly similar (rootmean-square deviation (RMSD) for maximum common structure = 0.28 A, Figure 11, given their structural similarity. As observed earlier for compounds with the same head group,41,42the 2-aminoquinoline head groups of both compounds interacted with the Glu597 side chain and Trp592 main chain carbonyl group by charge and H-bond interactions as well as with the heme porphyrin ring, forming multiple rr-interactions (Figure 8). Additionally, the tail parts of both molecules showed identical interactions with the heme propionate (charge interaction by the tail primaryamine in 16 or the secondary amine in 24), Tyr711 (H-bond by / 2-hydroxyl), and Trp683 (edge-to-face ^-interaction by phenyl ring), except for additional H-bonds with BH4 and solvent water in the binding mode of 16 (Figure 8). However, the docking scores (-12.76 and -11.60 kcal / mol for compounds 16 and 24, respectively) failed to explain their experimental binding affinity difference (AAGBmd > 6.5 kcal / mol based on their Kt values). Apparently, the docking calculation underestimated the contribution from the additional H-bonds with BH4 and solvent water in 16.

[0218] Because of the discrepancy between the experimental binding affinity and the predicted value from docking results, a 100-ns molecular dynamics (MD) simulation of each complex in the SPC solvent model box was conducted to enhance the quality of the binding model. In the dockinggenerated binding mode of 24, the methyl group on the tail amino group pointed toward a solvent-exposed vestibule of the binding site, preventing its solvation by water molecules (Figure 8, panel B). However, since the docking protocol only allows binding mode predictions with fixed water molecules, its scoring function is unreliable for accurately predicting the solvation effect. Therefore, the MD-generated trajectories enabling flexible water positions could be useful for the theoretical quantification of solvation effects on the tail amino groups.

[0219] As most interactions of both molecules were strong polar interactions and due to the head groups’ well-known tight interactions in the substrate binding site,41,42the binding modes of the ligands were highly stable based on the RMSD during the simulations (Figure 9, panel D). The head part RMSD was less than 0.8 A during each simulation in every frame (Figure 12, panels B and D), indicating its extremely stable binding mode. Additionally, the tail part of 16 maintained its stable RMSD (Figure 12, panel C) and distances for interactions (Figure 9, panels E-G) in its binding mode from the docking result (Figure 8, panel A and Figure 8, panel C). However, compared to its docking-predicted binding mode (Figure 8, panels B and D), the tail secondary amino group of 24 formed an additional H-bond with BHi and kept the distance (Figure 9, panels B and G). At the same time, the charge interaction with the heme propionate showed slightly unstable distances after ~20 ns of simulation (Figure 9, panel F).

[0220] To enable the interactions of the tail amino group with the heme propionate and BH4, the methyl group of 24 was exposed to the solvent-accessible area of the binding site (Figure 9, panel B), pointing away from the phenyl ring (dihedral angle C1-C2-N-C3 = -180° in Figure 10, panel B). Thus, based on the radial distribution function (g(r) in Figure 10, panel C of water molecules from the amine nitrogen, 24 showed a disrupted solvent shell with a major g(r) peak at 4.7 Acompared to that of 16 at 3.1 A, implying a well-established hydrated shell around the amine cation in 16 but not in 24. Notably, considering the gap between the two major peaks (1.6 A) and the typical C-N bond length (1.5 A), methyl substitution mainly contributes to the disruption of the hydration shell around the tail amino group in 24.

[0221] Due to the positional instability of the amine caused by the solvent-exposed methyl group, the distance between the amino group and the heme propionate ion, which is a determinant for their charge interaction, was relatively unstable throughout most 24 trajectories (Figure 9, panel F). Moreover, starting from 73 ns of the simulation, the terminal methyl group on the tail amino group in 24 rotated with a dihedral angle of -60° for 1.5 ns (Figure 10, panel B), exposing its proton to the solvent (Figure 13). Although this rotation enables additional solvation of the tail amino group, the rotated methyl group disrupts the charge interaction with heme by staying away from the heme propionate ion up to ~6 A (Figure 9, panel F), which is no longer available for charge interaction. Thus, the additional methyl substitution could reduce potency by disrupting the tail amino group solvation and / or charge interaction with the heme propionate.

[0222] The molecular mechanics with generalized Bom and surface area (MM / GBSA) technique was employed to quantify the binding affinity reflecting the solvation effect. Appropriate frames were sampled from the MD trajectories based on the protein-ligand complex energy (Figure 14, panels A and B), and the water molecules within 3 A from the ligand were included to generate microsolvation models (Figure 15). This enables a prediction of the solvation effect for the ammonium ion but disturbs the accurate calculation for the whole protein solvation energy due to its underlying calculation protocol using the implicit solvent model. However, even if the calculation of absolute binding free energy ( lGsind) is disturbed, it would be more accurate to predict the difference between the binding free energies of the two molecules ( Gsimi). As a result, the mean difference in lGsind was 6.01 kcal / mol (Figure 14, panel C), which is quite similar to the experimental value ( lGBind > 6.5 kcal / mol). Therefore, disturbed solvation by the additional methyl group on the tail ammonium would be one of the main reasons for its detrimental effect on the binding affinity.

[0223] In vivo pharmacokinetics of compound 16 in C57BL / 6 Mice

[0224] The pharmacokinetics of 16 were carried out in male C57BL / 6 mice after single intravenous (IV) and oral (PO) doses. Plasma and brain concentrations were measured over 48 h using a tested LC-MS / MS method (LLOQ 2.5 ng / mL). After intravenous dosing (iv, 3 mg / kg), 16showed a high initial plasma concentration (Cmax) of 654.08 ng / mL with an early Tmax of 0.083 h. The AUCiast was 654.03 h ng / mL, and the terminal half-life (ti / 2) was relatively short at 2.49 h (Table 3). Systemic clearance was high at 74.6 mL / min / kg, and the steady-state volume of distribution (Vss) was large 16.08 L / kg. This indicates rapid elimination from plasma and extensive distribution in tissues. After oral dosing (po, 10 mg / kg), 16 had a lower plasma Cmax of 86.51 ng / mL at 1.0 h. The AUCiast was 356.54 h ng / mL, with a longer terminal half-life (ti / 2) of 7.96 h and a high apparent distribution volume (Vss) of 222.69 L / kg. This resulted in a low oral bioavailability (%F) of 16.4% and suggests limited systemic availability even with measurable plasma levels (Table 3). In the brain, oral dosing showed a delayed Tmax of 12.0 h and a peak concentration of 172.0 ng / g, with 24 brains contributing over various time points. This supports a time-dependent accumulation in the CNS rather than quick penetration. Overall, these findings show that 16 has high clearance, low oral bioavailability, and a large distribution volume, with moderate and delayed exposure in the brain. This is consistent with extensive distribution in the body and limited CNS exposure after oral dosing in mice.

[0225] Table 3: Key Pharmacokinetic Parameters of compound 16 in Male C57BL / c Mice

[0226] Mat Rou Dose TmaxaC0 / AUCiast(h*ng / mL) T1 / 2 CL Vss%F rix te (mg / (h) Cmax(h) (mL (L / k

[0227] kg) (ng / / min g)

[0228] mL) / kg)

[0229] Plas iv 3 0.08 654. 654.03 2.49 74.6 16.0mapo 10 1.00 86.5 356.54 7.96 - 222. 16.4 Mat Rou Dose TmaxCmaxAUCiastBrain-Kp Brai

[0230] rix te (mg / (h) (ng / (h*ng / g) (Cmax) n- kg) g) Kp

[0231]

[0232] n po 10 12.0 172. - - 24.0 - Assuming brain density = 1.00 g / mL (1 ng / g ~ 1 ng / mL)

[0233] Conclusion

[0234] In this study, we developed a series of inhibitors with a 2-aminoquinoline head and a tail of a phenyl ring with two substituents at various positions. After ruling out any bulkier alkyl groups, initial testing with different substituents at the 6-position of the 2-aminoquinoline led to fluorine as the favored group for further development. Extensive trials focused on where and whatsubstituents are most effective on the phenyl ring. We concluded that (1) an w / Ao-substituent is too close to the heme propionates and generates potential steric clashes, although the ortho-hydroxyl group forces the phenyl ring into a vertical orientation relative to the heme plane, thereby avoiding clashes with propionates; (2) dual meta- and / wc / -substituents showed good binding affinity because both substituents have room to extend beyond the heme binding active site, interacting with propionate or other protein residues; (3) primary aminomethyl group as one of the two substituents is beneficial for good potency, as it can form strong H-bonds with propionate A and / or BH4, while a secondary amino group leads to poor (or no) binding affinity. A molecular mechanics calculation with the generalized Bom and surface area (MM / GBSA) technique indicated that the extra methyl group on the tail aminomethyl group disturbed solvation around the amine. Compound 16, with / iie / a-ami nomethyl and / % / ra-hydroxyl groups, is the best inhibitor in this series with K = 16 nM, hn / he selectivity of 1858, and hn / hi selectivity of 2919, and good membrane permeability. A docking study revealed extensive favorable interactions from both substituents of 16 to propionate A, BH4, a water molecule, and Tyr711 (Figure 8).

[0235] Experimental Section

[0236] Chemistry

[0237] General procedures

[0238] All reagents were purchased from Sigma-Aldrich, Combi-blocks, and Oakwood. Anhydrous solvents (THF, 1,4-dioxane, CH2CI2, MeOH, EtsN, and DMF) were distilled before use. Metal catalysts bis(triphenylphosphine)palladium(II) di chloride, copper(I) iodide, and Pd / C [10 wt % loading (dry basis), matrix carbon powder, and wet support] were purchased from Sigma-Aldrich. Thin layer chromatography (TLC) was performed on silica gel 60 F254 precoated plates (0.25 mm) from Silicycle, and components were visualized by ultraviolet light (254 nm) and / or KMnO4, ninhydrin stain, and phosphomolybdic acid stain.JH NMR spectra were recorded at 500 MHz, using a Bruker Avance III 500 (direct cryoprobe), and13C NMR spectra were obtained at 126 MHz using the same instrument in CDCh, CD3OD, or DMSO. Chemical shifts are reported in parts per million, and multiplicities are indicated by s = singlet, d = doublet, t = triplet, q = quartet, sep = septet, dd = doublet of doublet, dt = doublet of triplet, and m = multiplet. Coupling constants J were reported in Hz. High-resolution mass spectral data were obtained on an Agilent 6210 LC-TOF spectrometer in the positive ion mode using electrospray ionization with an Agilent G1312A HPLC pump and an Agilent G1367B autoinjector at the Integrated Molecular StructureEducation and Research Center (TMSERC), Northwestern University. The purity of all final target compounds was found to be >95% by HPLC. Flash column chromatography was performed on an Agilent 971-FP automated flash purification system with a Varian column station and various Silicycle cartridges (4-80 g, 40-63 pm, 60 A).

[0239] 7-(3-(Aminomethyl)phenyl)-6-fluoro-4-methylquinolin-2-amine dihydrochloride (7).

[0240] Compound 38 (0.14 g, 0.24 mmol) was treated with excess hydrogen chloride solution (2 mL, 4.0 M in 1,4-dioxane) at 0 °C. The reaction mixture was stirred for 16 h at 25 °C. The solvent was removed under reduced pressure to afford the dihydrochloride salt 7 as a white solid (0.06 g, 68%). 'HNMR (500 MHz, CD3OD) 87.97 - 7.84 (m, 3H), 7.77 (d, J= 9.0 Hz, 1H), 7.71 - 7.62 (m, 2H), 7.05 (s, 1H), 4.29 (s, 2H), 2.75 (s, 3H).13C NMR (125 MHz, CD3OD) 8 158.1 (d, J= 248.2 Hz), 155.3, 154.2 (d, J=.7 Hz), 136.2, 135.2, 135.1 (d, J= 17.6 Hz), 133.8, 131.0 (d, J= 2.5 Hz), 130.8 (d, J= 2.5 Hz), 130.7, 130.6, 123.6 (d, J= 10.0 Hz), 120.5 (d, J= 3.7 Hz), 114.5, 112.7 (d, J= 26.4 Hz), 44.1, 19.4. HRMS calcd for C17H17FN3+: 282.1401; found, 282.1408.

[0241] 7-(3-(Aminomethyl)phenyl)-6-chloro-4-methylquinolin-2-amine dihydrochloride (8).

[0242] Compound 39 (0.16 g, 0.268 mmol) was treated with excess hydrogen chloride solution (2 mL, 4.0 M in 1,4-dioxane) at 0 °C. The reaction mixture was stirred for 16 h at 25 °C. The solvent was removed under reduced pressure to afford the dihydrochloride salt 8 as a white solid (0.07 g, 77%). ’HNMR (500 MHz, CD3OD) 88.21 (s, 1H), 7.72 (s, 1H), 7.68 (s, 1H), 7.62 (q, J= 2.8 Hz, 3H), 7.02 (s, 1H), 4.25 (s, 2H), 2.74 (s, 3H). 'H NMR (500 MHz, CD3OD) 88.21 (s, 1H), 7.72 (s, 1H), 7.68 (s, 1H), 7.62 (q,.7= 2.8 Hz, 3H), 7.02 (s, 1H), 4.25 (s, 2H), 2.74 (s, 3H).13C NMR (125 MHz, CD3OD) 8154.3, 152.4, 143.7, 138.7, 134.5, 133.5, 129.8, 129.6, 129.2, 128.9, 128.8, 126.1, 122.0, 119.7, 113.3, 42.7, 17.9. HRMS calcd for C17H17ClN3: 298.1106; found, 298.1115.

[0243] 2-(2-Amino-6-fluoro-4-methylquinolin-7-yl)-4-(aminomethyl)phenol dihydrochloride (9). Compound 63 (0.10 g, 0.156 mmol) was treated with excess hydrogen chloride solution (2 mL, 4.0 M in 1,4-dioxane) at 0 °C. The reaction mixture was stirred for 16 h at 25 °C. The solvent was removed under reduced pressure to afford the dihydrochloride salt 9 as a white solid (0.04 g, 76%). 'HNMR (500 MHz, CD3OD) 87.85 (d, J= 10.4 Hz, 1H), 7.79 (d, J= 6.2 Hz, 1H), 7.48 (d, J = 2.9 Hz, 1H), 7.45 (dd, J = 8.3, 2.3 Hz, 1H), 7.07 (d, J= 8.3 Hz, 1H), 7.02 (s, lH), 4.13 (s, 2H), 2.74 (s, 3H).13C NMR (125 MHz, CD3OD) 8 157.3 (d, J = 246.9 Hz), 155.7, 153.8, 152.9, 131.9, 131.8, 131.0, 123.9, 122.0 (d, J= 8.8 Hz), 121.7, 120.3, 116.0, 112.8, 110.3 (d, J= 25.2 Hz), 42.4, 18.0. HRMS calcd for C17H17FN3O+298.1350; found, 298.1358.2-(2-Amino-6-fluoro-4-methylquinolin-7-yl)-5-(aminomethyl)phenol dihydrochloride (10). Compound 64 (0.12 g, 0.187 mmol) was treated with excess hydrogen chloride solution (2 mL, 4.0 M in 1,4-dioxane) at 0 °C. The reaction mixture was stirred for 16 h at 25 °C. The solvent was removed under reduced pressure to afford the dihydrochloride salt 10 as a white solid (0.05 g, 80%). 'HNMR (500 MHz, CD3OD) 57.83 (d, J= 10.3 Hz, 1H), 7.74 (d, J= 6.2 Hz, 1H), 7.41 (d, J = 7.2 Hz, 1H), 7.09 (d, J = 7.7 Hz, 2H), 7.00 (d, J = 1.2 Hz, 1H), 4.14 (s, 2H), 2.72 (d, J = 1.1 Hz, 3H).13C NMR (125 MHz, CD3OD) 8 158.2, 156.3, 155.4, 153.8, 152.9, 152.9, 135.4, 131.9, 131.9, 131.8, 131.5, 122.1, 122.0 (d, J= 26.4 Hz), 120.3 (d, J=3.7Hz), 119.3, 115.9, 112.8, 110.4 (d, J= 25.2 Hz), 42.6, 18.8. HRMS calcd for C17H17FN3O+: 298.1350; found, 298.1360.

[0244] 2-(2-Amino-6-fluoro-4-methylquinolin-7-yl)-5-(2-aminoethyl)phenol dihydrochloride (11). Compound 65 (0.11 g, 0.167 mmol) was treated with excess hydrogen chloride solution (2 mL, 4.0 M in 1,4-dioxane) at 0 °C. The reaction mixture was stirred for 16 h at 25 °C. The solvent was removed under reduced pressure to afford the dihydrochloride salt 11 as a white solid (0.05 g, 80%). ‘H NMR (500 MHz, CD3OD) 87.83 (d, J= 10.3 Hz, 1H), 7.74 (d, J= 6.2 Hz, 1H), 7.33 (d, J= 8.1 Hz, 1H), 7.00 (s, 1H), 6.96 - 6.91 (m, 2H), 3.26 (t, J= 7.8 Hz, 2H), 3.01 (t, J= 7.8 Hz, 2H), 2.73 (s, 3H).13C NMR (125 MHz, CD3OD) 8 157.4 (d, J= 248.2 Hz), 155.2, 153.7, 152.9 (d, J = 3.7 Hz), 139.2, 132.3, 131.9, 131.3, 121.8 (d, J = 8.8 Hz), 120.3 (d, J = 7.5 Hz), 120.1, 119.5, 115.7, 112.6, 110.3 (d, J = 26.4 Hz), 40.3, 33.0, 18.0. HRMS calcd for C18H19FN3O+: 312.1507; found, 312.1521.

[0245] 7-(5-(2-Aminoethyl)-2,3-difluorophenyl)-6-fluoro-4-methylquinolin-2-amine dihydrochloride (12). Compound 66 (0.14 g, 0.221 mmol) was treated with excess hydrogen chloride solution (2 mL, 4.0 M in 1,4-dioxane) at 0 °C. The reaction mixture was stirred for 16 h at 25 °C. The solvent was removed under reduced pressure to afford the dihydrochloride salt 12 as a white solid (0.07 g, 81%). ‘HNMR (500 MHz, CD3OD) 87.95 (d, J= 10.4 Hz, 1H), 7.86 (d, J = 6.1 Hz, 1H), 7.50 - 7.43 (m, 1H), 7.36 (q, J= 2.9 Hz, 1H), 7.08 (d, J= 1.3 Hz, 1H), 3.30 (t, J = 7.6 Hz, 2H), 3.10 (t, J= 7.7 Hz, 2H), 2.75 (s, 3H).13C NMR (125 MHz, CD3OD) 8 156.6 (d, J = 248.2 Hz), 154.0, 152.8, 149.6, 147.9, 145.9, 139.13, 134.2, 132.1, 127.5 (d, J= 20.1 Hz), 126.5, 124.1 (d, J= 12.6 Hz), 123.0 (d, J= 8.8 Hz), 120.1, 118.3 (d, J= 17.6 Hz), 113.6, 111.0 (d, J = 25.2 Hz), 40.0, 32.2, 18.1. HRMS calcd for C18H17F3N3+: 332.1369; found, 332.1380.

[0246] 7-(2,3-Difluoro-5-(2-(methylamino)ethyl)phenethyl)-6-fluoro-4-methylquinolin-2-amine dihydrochloride (13). To a solution of 71 (0.14 g, 0.210 mmol) in dry THF (3 mL) at 0 °Cunder a nitrogen atmosphere was added NaH (60% dispersion in mineral oil 0.02 g, 0.42 mmol) followed by iodomethane (0.04 g, 0.31 mmol). The reaction mixture was elevated to room temperature and was stirred for 16 h. After the completion of reaction, it was quenched with a saturated solution of NH4CI (5 mL), and the product was extracted with EtOAc (3 × 10 mL). The solution was dried over anhydrous Na2SO4, and the solvents were removed under reduced pressure. The product obtained was treated with excess hydrogen chloride solution (4.0 M in EtOAc) at 0 °C. The reaction mixture was stirred for 24 h at 25 °C. The solvent was removed under reduced pressure to afford dihydrochloride salt 13 as a white solid (0.07 g, 73%). 'H NMR (500 MHz, CD3OD) 5 7.79 (s, 1H), 7.73 (d, J= 10.4 Hz, 1H), 7.12 (t, J= 8.0 Hz, 1H), 7.06 (d, J= 6.0 Hz, 1H), 6.92 (s, 1H), 3.19 (d, J= 6.1 Hz, 7H), 3.15 - 3.10 (m, 2H), 2.93 (t, J= 7.8 Hz, 2H), 2.66 (s, 3H).13C NMR (125 MHz, CD3OD) 8 158.3 (d, J= 245.7 Hz), 150.6, 150.3 (dd, J= 246.9, 13.8 Hz), 147.9 (dd, J= 244.4, 12.6 Hz), 133.4 (t, J= 5.0 Hz), 132.5, 130.2 (d, J= 12.6 Hz), 125.8 (t, J= 3.15 Hz), 121.6, 119.4, 115.4 (d, J= 17.6 Hz), 113.2, 110.1 (d, J= 25.2 Hz), 40.2, 32.2, 29.5, 28.4, 27.9, 17.9. HRMS calcd for C21H23F3N3+: 374.1839; found, 374.1848.

[0247] 7-(5-(2-Aminoethyl)-2,3-difluorophenethyl)-6-fluoro-4-methylquinolin-2-amine dihydrochloride (14). Compound 71 (0.13 g, 0.197 mmol) was treated with excess hydrogen chloride solution (2 mL, 4.0 M in 1,4-dioxane) at 0 °C. The reaction mixture was stirred for 16 h at 25 °C. The solvent was removed under reduced pressure to afford the dihydrochloride salt 14 as a white solid (0.07 g, 81%). *HNMR (500 MHz, CD3OD) 87.76 (d, J= 10.4 Hz, 1H), 7.54 (d, J = 6.4 Hz, 1H), 7.12 (dd, J= 8.7, 7.2 Hz, 1H), 7.06 (d,,7= 5.9 Hz, 1H), 6.96 (s, 1H), 3.19 (q, J = 7.8 Hz, 4H), 3.15 - 3.09 (m, 2H), 2.94 (t, J = 7.8 Hz, 2H), 2.69 (s, 3H).13C NMR (125 MHz, CD3OD) 8 158.3 (d, J = 245.7 Hz), 153.7, 153.0, 150.3 (d, J = 246.9 Hz), 147.9 (d, J= 233.1 Hz), 134.7 (d, J = 20.1 Hz), 133.3, 132.2, 130.2 (d, J= 12.6 Hz), 125.7, 121.4 (d, J = 8.82 Hz), 119.0 (d, J= 5.0 Hz), 115.4 (d, J = 17.6 Hz), 112.5, 110.1 (d, J= 26.4 Hz), 40.1, 32.3, 29.5, 28.4, 18.0. HRMS calcd for C20H21F3N3+360.1682; found, 360.1693.

[0248] 7-(3-(Aminomethyl)-4-(cyclopropylmethoxy)phenyl)-6-fluoro-4-methylquinolin-2-amine dihydrochloride (15). Compound 79 (0.15 g, 0.230 mmol) was treated with excess hydrogen chloride solution (2 mL, 4.0 M in 1,4-dioxane) at 0 °C. The reaction mixture was stirred for 16 h at 25 °C. The solvent was removed under reduced pressure to afford the dihydrochloride salt 15 as a white solid (0.07 g, 79%). 'H NMR (500 MHz, CD3OD) 87.93 - 7.73 (m, 4H), 7.28 (d, J= 8.3 Hz, 1H), 7.01 (s, 1H), 4.28 (s, 2H), 4.09 (d, J = 7.1 Hz, 2H), 2.73 (d, J= 1.2 Hz, 3H),1.49 - 1.38 (m, 1H), 0.76 - 0.68 (m, 2H), 0.52 - 0.44 (m, 2H).13C NMR (125 MHz, CD3OD) 5 155.4 (d, J= 239.4 Hz), 152.4, 151.3 (d, J= 3.7 Hz), 132.0 (d, J = 16.3 Hz), 130.9, 130.1, 129.6, 124.7, 120.1 (d, J= 6.3 Hz), 116.9, 111.3, 110.6, 109.6 (d, J= 26.4 Hz), 71.8, 37.2, 16.5, 8.0, 0.7. HRMS calcd for C21H23FN3O+: 352.1820; found, 352.1836.

[0249] 4-(2-Amino-6-fhioro-4-methylquinolin-7-yl)-2-(aminoniethyl)phenol dihydrochloride (16). Compound 80 (0.19 g, 0.296 mmol) was treated with excess hydrogen chloride solution (2 mL, 4.0 M in 1,4-di oxane) at 0 °C. The reaction mixture was stirred for 16 h at 25 °C. The solvent was removed under reduced pressure to afford the dihydrochloride salt 16 as a white solid (0.08 g, 75%).XH NMR (500 MHz, CD3OD) 67.88 (d, J= 11.2 Hz, 1H), 7.79 (d, J= 6.8 Hz, 1H), 7.70 (t, J= 2.1 Hz, 1H), 7.64 (dt, J = 8.4, 2.0 Hz, 1H), 7.11 (d, J= 8.6 Hz, 1H), 7.00 (d, J= 1.3 Hz, 1H), 4.23 (s, 2H), 2.72 (s, 3H).13C NMR (125 MHz, CD3OD) 5 157.8, 157.0, 155.8, 153.9, 152.9, 152.8, 133.9 (d, J= 16.3 Hz), 132.5, 131.4 (d, J= 2.5 Hz), 125.3, 121.5 (d, J = 8.8 Hz), 119.9, 118.3 (d, J = 3.7 Hz), 115.2, 112.7, 111.1 (d, J = 26.4 Hz), 39.1, 18.0. HRMS calcd for C17H17FN3O+: 298.1350; found, 298.1355.

[0250] 7-(3-(Aminomethyl)-4-fluorophenyl)-6-fluoro-4-methylquinolin-2-anune dihydrochloride (17). Compound 81 (0.14 g, 0.233 mmol) was treated with excess hydrogen chloride solution (2 mL, 4.0 M in 1,4-dioxane) at 0 °C. The reaction mixture was stirred for 16 h at 25 °C. The solvent was removed under reduced pressure to afford the dihydrochloride salt 17 as a white solid (0.07 g, 83%). 'H NMR (500 MHz, CD3OD) 57.92 (t, J= 8.6 Hz, 2H), 7.85 (dd, J = 18.3, 5.3 Hz, 2H), 7.46 (t,.1= 92 Hz, 1H), 7.04 (s, 1H), 4.34 (s, 2H), 2.73 (s, 3H).13C NMR (125 MHz, CD3OD)5 161.4 (d, J = 250.7 Hz), 156.6 (d, J= 248.2 Hz), 154.0, 152.7, 132.7, 132.6 (d, J = 3.7 Hz), 132.2 (d, J = 8.8 Hz), 132.0, 130.9, 122.3 (d, J= 10.0 Hz), 120.9 (d, = 15.1 Hz), 119.1, 116.1 (d, J = 22.6 Hz), 113.2, 111.3 (d, J = 25.2 Hz), 36.5 (d, J= 3.7Hz), 18.0. HRMS calcd for C17H16F2N3+300.1307; found, 300.1320.

[0251] 5-(2-Amino-6-fluoro-4-methylquinolin-7-yl)-2-(aminomethyl)phenol dihydrochloride (18). Compound 82 (0.16 g, 0.249 mmol) was treated with excess hydrogen chloride solution (2 mL, 4.0 M in 1,4-dioxane) at 0 °C. The reaction mixture was stirred for 16 h at 25 °C. The solvent was removed under reduced pressure to afford the dihydrochloride salt 18 as a white solid (0.07 g, 78%). 'HNMR (500 MHz, CD3OD) 87.90 (d, J= 11.1 Hz, 1H), 7.79 (d, J= 6.6 Hz, 1H), 7.49 (d, J= 7.8 Hz, 1H), 7.26 (t, J= 1.8 Hz, 1H), 7.21 (dt, J= 7.8, 1.7 Hz, 1H), 7.02 (s, 1H), 4.22 (s, 2H), 2.73 (s, 3H)13C NMR (125 MHz, CD3OD) 8 156.6 (d, J = 246.9 Hz), 156.1, 154.0, 152.7, 136.5,133.8 (d, J = 17.6 Hz), 132.6, 130.7, 122.2 (d, J= 10.0 Hz), 120.2 (d, J= 13.8 Hz), 119.0, 115.4 (d, = 2.5 Hz), 113.1, 111.2 (d, J= 26.4 Hz), 38.9, 18.0. HRMS calcd for C17H17FN3O+298.1350; found, 298.1356.

[0252] 7-(4-(Aminomethyl)-3-fluorophenyl)-6-fluoro-4-methylquinolin-2-annne dihydrochloride (19). Compound 83 (0.17 g, 0.283 mmol) was treated with excess hydrogen chloride solution (2 mL, 4.0 M in 1,4-dioxane) at 0 °C. The reaction mixture was stirred for 16 h at 25 °C. The solvent was removed under reduced pressure to afford the dihydrochloride salt 19 as a white solid (0.08 g, 82%). ’H NMR (500 MHz, CD3OD) 87.94 (d, J= 11.2 Hz, 1H), 7.86 (d, J = 6.6 Hz, 1H), 7.73 (t, J= 7.9 Hz, 1H), 7.66 - 7.59 (m, 2H), 7.05 (s, 1H), 4.33 (s, 2H), 2.74 (s, 3H).13C NMR (125 MHz, CD3OD) 8 161.0 (d, J = 248.2 Hz), 156.5 (d, J = 248.2 Hz), 154.0, 152.7 (d, J= 3.7 Hz), 137.4 (d, J= 7.5 Hz), 132.5, 132.1 (d, J= 16.3 Hz), 131.4 (d, J= 3.7 Hz), 125.4, 122.6 (d, J= 8.8 Hz), 120.9 (d, J= 16.3 Hz), 119.1 (d, J= 2.5 Hz), 116.2 (dd, J= 22.6, 3.7 Hz), 113.4, 111.5 (d, J= 26.4 Hz), 36.4, 18.0. HRMS calcd for C17H16F2N3+: 300.1307; found, 300.1319.

[0253] 2-(2-Amino-6-fluoro-4-methylquinolin-7-yl)-4-((methylamino)methyl)phenol dihydrochloride (20). To a solution of 63 (0.18 g, 0.280 mmol) in dry THF (3 mL) at 0 °C under a nitrogen atmosphere was added NaH (60% dispersion in mineral oil 0.02 g, 0.560 mmol) followed by iodomethane (0.06 g, 0.420 mmol). The reaction mixture was elevated to room temperature and was stirred for 16 h. After the completion of reaction, it was quenched with a saturated solution of NH4CI (5 mL), and the product was extracted with EtOAc (3 * 10 mL). The solution was dried over anhydrous Na2SO4, and the solvents were removed under reduced pressure. The product obtained was treated with excess hydrogen chloride solution (2 mL, 4.0 M in EtOAc) at 0 °C. The reaction mixture was stirred for 24 h at 25 °C. The solvent was removed under reduced pressure to afford dihydrochloride salt 20 as a white solid (0.08 g, 76%). 'll NMR (500 MHz, CD3OD) 8 8.07 (s, 1H), 7.81 (d, J= 10.3 Hz, 1H), 7.48 (d, J= 3.2 Hz, 1H), 7.44 (dd, J= 8.4, 2.4 Hz, 1H), 7.06 (d, J= 8.3 Hz, 1H), 6.97 (s, 1H), 4.12 (s, 2H), 3.21 (s, 3H), 2.70 (s, 3H).13C NMR (125 MHz, CD3OD) 8 157.2 (d, J = 246.9 Hz), 155.7, 153.1, 132.3, 131.8 (d, J = 2.5 Hz), 130.9, 123.9, 122.2, 121.8, 120.8, 116.0, 113.5, 110.3 (d, J= 26.4 Hz), 42.4, 27.9, 17.9. HRMS calcd for C18H19FN3O+ 312.1507; found, 312.1500.

[0254] 2-(2-Amino-6-fluoro-4-niethylquinolin-7-yl)-5-((methylamino)methyl)phenol dihydrochloride (21). To a solution of 64 (0.23 g, 0.312 mmol) in dry THF (3 mL) at 0 °C undera nitrogen atmosphere was added NaH (60% dispersion in mineral oil 0.03 g, 0.660 mmol) followed by iodomethane (0.06 g, 0.460 mmol). The reaction mixture was elevated to room temperature and was stirred for 16 h. After the completion of reaction, it was quenched with a saturated solution of NH4CI (5 mL), and the product was extracted with EtOAc (3 × 10 mL). The solution was dried over anhydrous Na2SO4, and the solvents were removed under reduced pressure. The product obtained was treated with excess hydrogen chloride solution (2 mL, 4.0 M in EtOAc) at 0 °C. The reaction mixture was stirred for 24 h at 25 °C. The solvent was removed under reduced pressure to afford dihydrochloride salt 21 as a white solid (0.11 g, 80%). 'H NMR (500 MHz, CD3OD) 5 8.00 (s, 1H), 7.81 (d, J= 10.3 Hz, 1H), 7.41 (d, J= 7.7 Hz, 1H), 7.10 (d, J= 8.7 Hz, 2H), 6.96 (s, 1H), 4.15 (s, 2H), 3.20 (s, 3H), 2.69 (s, 3H).13C NMR (125 MHz, CD3OD) 8 157.2 (d, J= 250.7 Hz), 155.4, 153.1, 150.6, 135.3, 132.3, 131.6 (d, J= 2.5 Hz), 131.3, 122.2, 120.7, 119.3, 115.9, 113.4, 110.3 (d, J = 26.4 Hz), 42.6, 27.76, 17.9. HRMS calcd for C18H19FN3O+ 312.1507; found, 312.1503.

[0255] 2-(2-Amino-6-fluoro-4-methylquinolin-7-yl)-5-(2-(methylamino)ethyl)phenol dihydrochloride (22). To a solution of 65 (0.16 g, 0.242 mmol) in dry THF (3 mL) at 0 °C under a nitrogen atmosphere was added NaH (60% dispersion in mineral oil 0.02 g, 0.484 mmol) followed by iodomethane (0.05 g, 0.363 mmol). The reaction mixture was elevated to room temperature and was stirred for 16 h. After the completion of reaction, it was quenched with a saturated solution of NH4CI (5 mL), and the product was extracted with EtOAc (3 x 10 mL). The solution was dried over anhydrous Na2SO4, and the solvents were removed under reduced pressure. The product obtained was treated with excess hydrogen chloride solution (2 mL, 4.0 M in EtOAc) at 0 °C. The reaction mixture was stirred for 24 h at 25 °C. The solvent was removed under reduced pressure to afford dihydrochloride salt 22 as a white solid (0.08 g, 83%). 'H NMR (500 MHz, CD3OD) 8 8.00 (s, 1H), 7.80 (d, J= 10.4 Hz, 1H), 7.33 (dd, J= 8.3, 1.3 Hz, 1H), 6.94 (d, J = 6.2 Hz, 3H), 3.26 (t, J= 7.8 Hz, 2H), 3.21 (s, 3H), 3.01 (t, J= 7.8 Hz, 2H), 2.70 (s, 3H).13C NMR (125 MHz, CD3OD) 8 157.3 (d, J= 248.2 Hz), 155.2, 153.1, 139.1, 132.3, 131.3, 122.1, 120.7, 120.3, 119.5, 115.7, 113.3, 110.2 (d, J = 26.4 Hz), 40.3, 33.0, 27.7, 17.9. HRMS calcd for C19H21FN3O+ 326.1663; found, 326.1668.

[0256] 7-(4-(Cyclopropylmethoxy)-3-((methylamino)methyl)phenyl)-6-fluoro-4-methylquinolin-2-amine dihydrochloride (23). To a solution of 79 (0.13 g, 0.202 mmol) in dry THF (3 mL) at 0 °C under a nitrogen atmosphere was added NaH (60% dispersion in mineral oil0.02 g, 0.404 mmol) followed by iodomethane (0.04 g, 0.303 mmol). The reaction mixture was elevated to room temperature and was stirred for 16 h. After the completion of reaction, it was quenched with a saturated solution of NH4CI (5 mL), and the product was extracted with EtOAc (3 x 10 mL). The solution was dried over anhydrous Na2SO4, and the solvents were removed under reduced pressure. The product obtained was treated with excess hydrogen chloride solution (2 mL, 4.0 M in EtOAc) at 0 °C. The reaction mixture was stirred for 24 h at 25 °C. The solvent was removed under reduced pressure to afford dihydrochloride salt 23 as a white solid (0.07 g, 79%). 'HNMR (500 MHz, CD3OD) 58.10 (s, 1H), 7.86 (d, J= 11.2 Hz, 1H), 7.81 - 7.73 (m, 2H), 7.29 (d, J= 8.6 Hz, 1H), 6.97 (s, 1H), 4.28 (s, 2H), 4.10 (d, J= 7.1 Hz, 2H), 3.24 (s, 3H), 2.70 (s, 3H), 1.48 - 1.39 (m, 1H), 0.72 (d, J = 8.2 Hz, 2H), 0.48 (d, J = 4.9 Hz, 2H).13C NMR (125 MHz, CD3OD) 5 158.3, 157.1 (d, J = 246.9 Hz), 153.6, 133.3, 132.0, 131.6 (d, J= 3.7 Hz), 128.9, 126.9, 122.4, 122.1, 119.3, 112.7, 111.6 (d, J = 25.2 Hz), 73.7, 39.2, 28.3, 18.3, 10.0, 2.7. HRMS calcd for C22H25FN3O: 366.1976; found, 366.1998.

[0257] 4-(2-Amino-6-fluoro-4-methylquinolin-7-yl)-2-((methylamino)methyl)phenol dihydrochloride (24). To a solution of 80 (0.21 g, 0.326 mmol) in dry THF (3 mL) at 0 °C under a nitrogen atmosphere was added NaH (60% dispersion in mineral oil 0.02 g, 0.652 mmol) followed by iodomethane (0.05 g, 0.439 mmol). The reaction mixture was elevated to room temperature and was stirred for 16 h. After the completion of reaction, it was quenched with a saturated solution of NH4CI (5 mL), and the product was extracted with EtOAc (3 x 10 mL). The solution was dried over anhydrous Na2SO4, and the solvents were removed under reduced pressure. The product obtained was treated with excess hydrogen chloride solution (2 mL, 4.0 M in EtOAc) at 0 °C. The reaction mixture was stirred for 24 h at 25 °C. The solvent was removed under reduced pressure to afford dihydrochloride salt 24 as a white solid (0.09 g, 72%). 'H NMR (500 MHz, CD3OD) 58.07 (S, 1H), 7.85 (d, J= 11.2 Hz, 1H), 7.71 (s, 1H), 7.64 (dt, J= 8.4, 2.0 Hz, 1H), 7.12 (d, J= 8.6 Hz, 1H), 6.96 (s, 1H), 4.23 (s, 2H), 3.24 (s, 3H), 2.69 (s, 3H).13C NMR (125 MHz, CD3OD) 5 156.9, 156.8 (d, J= 246.9 Hz), 153.2, 133.0, 131.38 (d, J= 3.7 Hz), 131.32 (d, J= 3.7 Hz), 125.5, 121.8, 119.9, 118.8, 115.3, 113.4, 111.1 (d, J= 25.2 Hz), 39.2, 27.8, 17.8. HRMS calcd for C18H19FN3O+ 312.1507; found, 312.1503.

[0258] Accession Codes

[0259] PDB codes for the X-ray crystal structures described in this study are as follows (see Table 4 for details): rnNOS-7, 9MYX; mNOS-10, 9MYY; rnNOS-11, 9MYZ; mNOS-15, 9MY0;hnNOS-7, 9MYU; hnNOS-10, 9MYV; hnNOS-11, 9MYW; heNOS-7, 9MZ1; heNOS-10, 9MZ2; heNOS-11, 9MZ3; heNOS-15, 9MZ4

[0260] Abbreviations

[0261] NO, nitric oxide; BBB, blood-brain barrier; Caco-2, cancer coli-2; CNS, central nervous system; FMN, Flavin mononucleotide; eNOS, endothelial nitric oxide synthase; FEB, (6R)-5,6,7,8-tetrahydrobiopterin; hnNOS, human neuronal nitric oxide synthase; heNOS, human endothelial nitric oxide synthase; hiNOS, human inducible nitric oxide synthase; iNOS, inducible nitric oxide synthase; NADPH, reduced nicotinamide adenine dinucleotide phos-phate; nNOS, neuronal nitric oxide synthase; NO, nitric oxide; Pe, effective permeability; PAMPA, parallel artificial membrane permeability assay; rnNOS, rat neuronal nitric oxide synthase; TLC, thin-layer chromatography; SAR, Structure-Activity Relationship; ESP, Electrostatic Potential; DFT, Density functional theory; MOMCl, Methoxymethyl chloride; RMSD, root-mean-square deviation; MD, molecular dynamics; MM, molecular mechanics; GBSA, generalized Born and surface area; BBB, blood brain barrier

[0262] References

[0263] 1. Kerwin, Jr. J. F.; Lancaster, J. R.; Feldman, P. L. Nitric Oxide: A New Paradigm for Second Messengers. J. Med. Chem. 1995, 38, 4343-4362.

[0264] 2. Vallance, P., Leiper, J. Blocking NO synthesis: how, where and why?. Nat. Rev. Drug Discovery. 2002, 1, 939-950.

[0265] 3. Vincent, S. R. Nitric oxide: a radical neurotransmitter in the central nervous system. Prog. Neurobiol. 1994, 42, 129-160.

[0266] 4. Bogdan, C. Nitric oxide and the immune response. Nat. Immunol. 2001, 2, 907-916.

[0267] 5. Palmer, R. M.; Ferrige, A. G.; Moncada, S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327, 524-526.

[0268] 6. Aiderton, W. K.; Cooper, C. E.; Knowles, R. G. Nitric oxide synthases: structure, function and inhibition. Biochem. J. 2001, 357, 593-615.

[0269] 7. Esplugues, J. V. NO as a signalling molecule in the nervous system. Br.; J. Pharmacol.

[0270] 2002, 135, 1079-1095.

[0271] 8. Wang, Y.; Newton, D. C.; Marsden, P. A. Neuronal NOS: Gene Structure, mRNA Diversity, and Functional Relevance. Crit. Rev. Neurobiol. 1999, 13, 21-43.9. Baranano, D. E.; Snyder, S. H. Neural roles for heme oxygenase: contrasts to nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 10996-11002.

[0272] 10. Roe, N. D.; Ren, J. Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases. Vasc. Pharmacol. 2012, 57, 168-172.

[0273] 11. Karpuzoglu, E.; Ahmed, S. A. Estrogen regulation of nitric oxide and inducible nitric oxide synthase (iNOS) in immune cells: implications for immunity, autoimmune diseases, and apoptosis. Nitric Oxide 2006, 15, 177-186.

[0274] 12. Hall, C. N.; Garthwaite, J. What is the real physiological NO concentration in vivo? Nitric Oxide. 2009, 21, 92-103.

[0275] 13. Torreilles, F.; Salman-Tabcheh, S.; Guérin, M.; Torreilles, J. Neurodegenerative disorders: the role of peroxynitrite. Brain Res. Rev. 1999, 30, 153-163.

[0276] 14. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M. T. D.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39, 44-84.

[0277] 15. Cobb, C. A.; Cole, M. P. Oxidative and Nitrative Stress in Neurodegeneration. Neurobiol. Dis. 2015, 84, 4-21.

[0278] 16. Uehara, T.; Nakamura, T.; Yao, D.; Shi, Z.-Q.; Gu, Z.; Ma, Y.; Masliah, E.; Nomura, Y.; Lipton, S. A. 5-Nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 2006, 441, 513-517.

[0279] 17. Silverman, R. B. Design of selective neuronal nitric oxide synthase inhibitors for the prevention and treatment of neurodegenerative diseases. Acc. Chem. Res. 2009, 42, 439-451. 18.

[0280] Mukherjee, P.; Cinelli, M. A.; Kang, S.; Silverman, R. B. Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain. Chem. Soc. Rev. 2014, 43, 6814-6838.

[0281] 19. Kobayashi, Y.; Ikeda, K.; Shinozuka, K.; Nara, Y.; Yamori, Y.; Hattori, K. L-nitroarginine increases blood pressure in the rat. Clin. Exp. Pharmacol. Physiol. 1991, 18, 397-399.

[0282] 20. Cinelli, M. A.; Do, H. T.; Miley, G. P.; Silverman, R. B. Inducible nitric oxide synthase: Regulation, structure, and inhibition. Med. Res. Rev. 2020, 40, 158-189.

[0283] 21. Southan, G. J.; Szabo, C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem. Pharmacol. 1996, 51, 383-394.22. Babu, B. R.; Griffith, O. W. Design of isoform-selective inhibitors of nitric oxide synthase. Curr. Opin. Chem. Biol. 1998, 2, 491-500.

[0284] 23. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties. ACS Chem. Neurosci. 2010, 1, 435-449.

[0285] 24. Rankovic, Z. CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure. J. Med. Chem. 2015, 58, 2584-2608.

[0286] 25. Mikitsh, J. L.; Chacko, A.-M. Pathways for small molecule delivery to the central nervous system across the blood-brain barrier. Perspect. Med. Chem. 2014, 6, PMC. SI 3384.

[0287] 26. Misra, A.; Ganesh, S.; Shahiwala, A.; Shah, S. P. Drug delivery to the central nervous system: a review. J. Pharm. Pharm. Sci. 2003, 6, 252-273.

[0288] 27. Di, L.; Rong, H.; Feng, B. Demystifying Brain Penetration in Central Nervous System Drug Discovery. J. Med. Chem. 2013, 56, 2-12.

[0289] 28. Yang, Z.; Misner, B.; Ji, H.; Poulos, T. L.; Silverman, R. B.; Meyskens, F. L.; Yang, S. Targeting Nitric Oxide Signaling with nNOS Inhibitors as a Novel Strategy for the Therapy and Prevention of Human Melanoma Antioxid. Redox Signaling 2013, 19, 433-4477.

[0290] 29. Tong, S.; Cinelli, M. A.; El-Sayed, N. S.; Huang, H.; Patel, A.; Silverman, R. B.; Yang, S. Inhibition of interferon-gamma-stimulated melanoma progression by targeting neuronal nitric oxide synthase (nNOS) Sci. Rep. 2022, 12, 1701.

[0291] 30. Tong, S.; Darwish, S.; Ariani, H. H. N.; Lozada, K. A.; Salehi, D.; Cinelli, M. A.; Silverman, R. B.; Kaur, K.; Yang, S. A Small Peptide Increases Drug Delivery in Human Melanoma Cells. Pharmaceutics 2022, 14, 1036.

[0292] 31. Huang, H.; Li, H.; Yang, S.; Chreifi, G.; Martasek, P.; Roman, L. J.; Meyskens, F. L.; Poulos, T. L.; Silverman, R. B. Potent and selective double-headed thiophene-2-carboximidamide inhibitors of neuronal nitric oxide synthase for the treatment of melanoma J. Med. Chem. 2014, 57, 686-700.

[0293] 32. Vasu, D.; Li, H.; Hardy, C. D.; Poulos, T. L.; Silverman, R. B. 2-Aminopyridines with a shortened amino sidechain as potent, selective, and highly permeable human neuronal nitric oxide synthase inhibitors. Bioorg. Med. Chem. 2022, 69, 116878.33. Kang, S.; Li, H.; Tang, W.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B.

[0294] 2-Aminopyridines with a Truncated Side Chain To Improve Human Neuronal Nitric Oxide Synthase Inhibitory Potency and Selectivity. J. Med. Chem. 2015, 58, 5548-5560.

[0295] 34. Do, H. T.; Wang, H.-Y.; Li, H.; Chreifi, G.; Poulos, T. L.; Silverman, R. B. Improvement of Cell Permeability of Human Neuronal Nitric Oxide Synthase Inhibitors Using Potent and Selective 2-Aminopyridine-Based Scaffolds with a Fluorobenzene Linker. J. Med. Chem. 2017, 60, 9360-9375.

[0296] 35. Ji, H.; Stanton, B. Z.; Igarashi, J.; Li, H.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Minimal Pharmacophoric Elements and Fragment Hopping, an Approach Directed at Molecular Diversity and Isozyme Selectivity. Design of Selective Neuronal Nitric Oxide Synthase Inhibitors. J. Am. Chem. Soc. 2008, 130, 3900-3914.

[0297] 36. Do, H. T.; Li, H; Chreifi, G.; Poulos, T. L.; Silverman, R. B. Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold. J. Med. Chem. 2019, 62, 2690-2707.

[0298] 37. Vasu, D. D. H. T.; Li, H.; Hardy, C. D.; Awasthi, A.; Poulos, T. L.; Silverman, R. B. Potent, Selective, and Membrane Permeable 2-Amino-4-substituted Pyridine-Based Neuronal Nitric Oxide Synthase Inhibitors. J. Med. Chem. 2023, 66, 9934-9953.

[0299] 38. Cinelli, M. A.; Li, H.; Chreifi, G.; Martasek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Simplified 2-Aminoquinoline-Based Scaffold for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition. Med. Chem. 2014, 57, 1513-1530.

[0300] 39. Cinelli, M. A.; Li, H.; Pensa, A. V.; Kang, S.; Roman, L. J.; Martasek, P.; Poulos, T. L.; Silverman, R. B. Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase. J. Med. Chem. 2015, 58, 8694-8712.

[0301] 40. Cinelli, M. A.; Li, H.; Chreifi, G.; Poulos, T. L.; Silverman, R. B. Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2-Aminoquinoline Inhibitors. J. Med. Chem. 2017, 60, 3958-3978.

[0302] 41. Pensa, A. V.; Cinelli, M. A.; Li, H.; Chreifi, G.; Mukherjee, P.; Roman, L. J.; Martasek, P.; Poulos, T. L.; Silverman, R. B. Hydrophilic, potent, and selective 7-substituted 2-aminoquinolines as improved human neuronal nitric oxide synthase inhibitors. J. Med. Chem.

[0303] 2017, 60, 7146-7165.42. Cinelli, M. A.; Reidl, C.; Li, H.; Chreifi, G.; Poulos, T.; Silverman, R. First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform- Specific Aspartate. J. Med. Chem. 2020, 63, 4528-4554.

[0304] 43. Johnson, B. M.; Shu, Y.-Z.; Zhuo, X.; Meanwell, N. A. Metabolic and Pharmaceutical Aspects of Fluorinated Compounds. J. Med. Chem. 2020, 63, 6315-6386.

[0305] 44. Li, H. Y.; Igarashi, J.; Jamal, J.; Yang, W. P.; Poulos, T. L. Structural Studies of Constitutive Nitric Oxide Synthases with Diatomic Ligands Bound J. Biol. Inorg. Chem. 2006, 11, 753-768.

[0306] 45. Raman, C. S.; Li, H.; Martasek, P.; Kral, V.; Masters, B. S. S.; Poulos, T. L. Crystal structure of constitutive endothelial nitric oxide synthase: A paradigm for pterin function involving a novel metal center. Cell 1998, 95, 939-950.

[0307] 46. Davydov, R.; Ledbetter-Rogers, A.; Martasek, P.; Larukhin, M.; Sono, M.; Dawson, J. H.; Masters, B. S. S.; Hoffman, B. M. EPR and ENDOR characterization of intermediates in the cryoreduced oxy-nitric oxide synthase heme domain with bound L-arginine or N-G-hydroxyarginine. Biochemistry 2002, 41, 10375-10381.

[0308] 47. Woodward, J. J.; Chang, M. M.; Martin, N. I.; Marietta, M. A. The second step of the nitric oxide synthase reaction: Evidence for ferric-peroxo as the active oxidant. J. Am. Chem. Soc. 2009, 131, 297-305.

[0309] 48. Labby, K. J.; Xue, F.; Kraus, J. M.; Ji, H.; Mataka, J.; Li, H.; Martasek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Intramolecular hydrogen bonding: A potential strategy for more bioavailable inhibitors of neuronal nitric oxide synthase. Bioorg. Med. Chem. 2012, 20, 2435-2443.

[0310] 49. Hevel, J. M.; Marietta, M. A. Nitric-oxide synthase assays Methods Enzymol. 1994, 233, 250-258.

[0311] 50. Konczol, A.; Muller, J.; Fbldes, E.; Beni, Z.; Vegh, K.; Kery, A.; Balogh, G. T. Applicability of a blood-brain barrier specific artificial membrane permeability assay at the early stage of natural product-based CNS drug discovery. J. Nat. Prod. 2013, 76, 655-663.

[0312] 51. Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 2003, 38, 223-232.

[0313] 52. Chen, D.; Zhao, M.; Tan, W.; Li, Y.; Li, X.; Li, Y.; Fan, X. Effects of Intramolecular Hydrogen Bonds on Lipophilicity. Eur. J. Pharm. Sci. 2019, 130, 100-106.Supporting Information (ST)

[0314] NOS Enzyme Inhibition Assay

[0315] The NOS inhibitory activity of the studied compounds was measured by the hemoglobin (Hb) NO capture assay, in which NO production was monitored by a rapid oxidation of oxyHb to metHb by NO. Purified recombinant full-length NOSs, including rat nNOS (rnNOS),1’2human nNOS (hnNOS),3human iNOS (hiNOS),4and human eNOS (heNOS),3were used in activity assays. These proteins were expressed in Escherichia coli and purified as described previously.1'4The assay was done in 100 mM HEPES buffer with 10% glycerol (pH 7.4) at 37 °C in the presence of 10 μM L-Arg, 10 μM H4B, 100 pM NADPH, 0.83 mM CaCl2, 320 units / mL of calmodulin, and 3 pM human oxyhemoglobin. In the case of iNOS, CaCh and calmodulin were omitted and replaced by HEPES buffer because iNOS activation is calcium-independent. The assay was performed in 96-well plates using a Biotek Gen5 microplate reader. The dispensing of NOS enzyme and hemoglobin was automated. After 30 s (maximum delay), NO production was read by monitoring the absorbance at 401 nm (resulting from the conversion of oxyhemoglobin to methemoglobin). The inhibition constants (Ki) for all NOSs were calculated from the ICso values of the dose-response curves using the Cheng-Prusoff equation: Ki = IC50 / (1 + [S] / Km)5and Km(human nNOS, 1.6 pM; rat nNOS, 1.3 pM; human eNOS, 3.9 pM; human iNOS, 8 pM).6Dose-response curves were constructed from ten to eleven test concentrations (10 mM to 10 nM), and ICso values were calculated by nonlinear regression using GraphPad Prism software. The calculated standard deviations from the dose-response curves of the assays were less than 10% with all NOSs.

[0316] Computational details

[0317] Most computational works were performed in the Maestro as a part of the Schrodinger Release 2023-2 (Schrodinger, LLC, New York, NY). All figures from the computational modeling were visualized using BIO VIA Discovery Studio 2024 Visualizer (Dassault Systemes, San Diego, CA). As the general procedure for protein preparation, the protein-ligand complex was subjected to the Protein Preparation Wizard7and minimized using the Prime8. In the minimization step using Prime, the ‘Automatic’ method, which combines the conjugate gradient and the truncated Newton method, was used, and the RMS gradient for convergence was 0.01 kcal / mol / A. All the structures were typed by the OPLS4 force field9during the calculation.To provide its ligand as a template for the ESP calculation, the hnNOS crystal structure in complex with 7-(3-(Aminomethyl)-4-(cyclopropylmethoxy)phenyl)-4-methylquinolin-2-amine (PDB ID: 6PO7)10was retrieved from the protein data bank (PDB, https: / / www.rcsb.org / )11and prepared as mentioned above. Each input ligand was generated by modifying the 6-position of the extracted ligand using the 3D builder in the Maestro. The ESP was calculated after the geometric optimization using the Jaguar module12at the DFT / B3LYP-D3 level of theory with the 6-31G+** basis set.

[0318] For generating the binding modes of 16 and 24, docking of each ligand into the hnNOS binding site was performed using the Glide13with extra precision (XP) module14. The receptor input for docking was prepared from the crystal structure of the hnNOS complexed with 10 (PDB ID: 9MYV). The receptor grid was generated as a grid box centered on the 10 ligand centroid in the structure, and the size was defined by the 10- A boundary from the ligand centroid. The ligand structures sketched in the ChemDraw Professional (Revvity Signals, Waltham, MA) were prepared using the LigPrep module. The nonpolar part of the ligand was softened by scaling the vdW radius of ligand atoms (80%) during the docking process. The binding mode for further modeling was selected by docking score and visual inspection.

[0319] The input system for the MD simulation was generated by the System Builder incorporated into the Desmond15from the docking-generated protein-ligand complex. The complex was solvated in the orthorhombic box of SPC water with a minimum distance of 10 A from the complex to the box boundary, and Na+and Cl−ions were added to neutralize the system, achieving a desired ionic strength of 0.15 M NaCl. The prepared system was subjected to a 5-step relaxation method provided by Desmond, and the production step was performed under the NPT ensemble (Nose-Hoover chain thermostat, Martyna-Tobias-Klein barostat) at 300 K for 100 ns. The MD trajectories and calculated energies were recorded every 5 ps and analyzed using the Maestro interface and Desmond module. Based on the protein-ligand complex energy during the simulation (Error! Reference source not found.), appropriate frames were sampled, including the water molecules within 3 A from the ligand, to generate microsolvation models for each ligand (Error! Reference source not found.). The micro solvation models were then subjected to the Prime MM / GBSA to calculate the compounds' relative binding free energy ( Gbind).

[0320] Table 4. Crystallographic data collection and refinement statistics

[0321] Data set" hnNOS R354A hnNOS R354A hnNOS R354AG357D-7 G357D-10 G357D-11 Data collection

[0322] PDB code 9MYU 9MYV 9MYW

[0323] Space group P2₁ P2₁ P2₁

[0324] Cell dimensions

[0325] a, Z>, c (A) 51.9 119.1 165.3 118.9 52.2 164.6 52.3 118.4 164.9 P (°) 90.06 90.00 90.05 Resolution (A) 2.15 (2.19-2.15) 2.15 (2.19-2.15) 2.30 (2.34-2.30) Rmerge 0.120 (2.813) 0.129 (2.372) 0.138 (2.521) Rpim0.061 (1.424) 0.049 (0.899) 0.073 (1.070) Rmeasure 0.135 (3.161) 0.138 (2.541) 0.135 (1.900) CC 1 / 2 0.988 (0.488) 0.998 (0.491) 0.971 (0.720)

[0326]

[0327] 6.6 (1.53)c8.7 (1.40)c6.1 (1.59)cNo. unique reflections 106613 (5219) 110978 (5998) 87948 (4419) Completeness (%) 97.9 (97.9) 99.9 (99.4) 98.8 (98.1) Redundancy 4.7 (4.7) 7.7 (7.8) 3.2 (3.0)

[0328] No. crystals 1 2 1

[0329] Wilson B factor (A) 45.7 43.6 40.6 Refinement

[0330] Resolution (A) 2.15 2.15 2.30

[0331] No. reflections used 102780 110841 86572

[0332]

[0333] No. atoms, Protein 13595 13582 13600 Ligand / ion 377 375 370

[0334] Water 378 635 592

[0335] R.m.s. deviations

[0336] Bond lengths (A) 0.008 0.007 0.007

[0337] Bond angles (°) 1.01 0.964 0.94Data set" rnNOS R349A-7 rnNOS R349A-10 rnNOS mNOS R349A-11 R349A-15 Data collection

[0338] PDB code 9MYX 9MYY 9MYZ 9MZ0 Space group C222i C222i C222i C222i Cell dimensions

[0339] a, b, c (A) 48.9 114.8 164.8 48.6 113.2 162.9 48.5 113.3 49.1 114.1

[0340] 162.7 164.0 Resolution (A) 1.82 (1.86-1.82) 1.83 (1.87-1.83) 1.92 (1.97- 1.94 (1.98- 1.92) 1.94) Rmerge 0.135 (3.755) 0.058 (5.221) 0.056 (4.103) 0.219 (8.076) Rpim0.043 (1.866) 0.025 (2.536) 0.024 (1.969) 0.064 (2.413) ^measure 0.142 (4.218) 0.064 (6.294) 0.061 (4.574) 0.229 (8.435) CC 1 / 2 0.998 (0.213) 1.000 (0.365) 0.999 (0.448) 0.997 (0.376) < Z / o7 > 14.1 (1.04)c12.1 (1.14)c6.8 (1.??)c6.6 (1.27)cNo. unique 42108 (2260) 40073 (2489) 34352 (2035) 34664 (2268) reflections

[0341] Completeness 99.7 (95.8) 99.6 (99.4) 98.7 (89.0) 100.0 (99.5) (%)

[0342] Redundancy 10.8 (4.9) 6.5 (6.0) 6.4 (5.0) 12.8 (12.2) No. crystals 2 1 1 2

[0343] Wilson B factor 34.5 43.3 48.2 39.7

[0344] (A)

[0345] Refinement

[0346] Resolution (A) 1.82 1.83 1.92 1.94

[0347] No. reflections 38503 38045 33417 32641 used

[0348]

[0349] Ligand / ion 76 87 88 91 Water 47 35 35 27

[0350] R.m.s. deviations

[0351] Bond lengths 0.007 0.006 0.007 0.007

[0352] (A)

[0353] Bond angles 1.01 0.96 0.97 1.04

[0354]

[0355] Data set" heNOS-7 heNOS-10 heNOS-11 heNOS-15 Data collection

[0356] PDB code 9MZ1 9MZ2 9MZ3 9MZ4

[0357] Space group P2₁ P2₁ P2₁ P2₁

[0358] Cell dimensions

[0359] a, b, c (A) 59.4 152.7 59.7 152.8 59.1 151.3 58.8 151.1 107.8 (°) 108.9 108.7 108.0 90.6

[0360] 90.9 90.7 90.8

[0361] Resolution (A) 2.05 (2.09- 1.99 (2.02- 1.95 (1.98- 1.94 (1.97-1.94)

[0362] 2.05) 1.99) 1.95)

[0363] Rmerge 0.110 (1.798) 0.170 (2.694) 0.234 (5.017) 0.157 (3.462) Rpim0.069 (1.162) 0.058 (1.331) 0.078 (1.800) 0.075 (1.654) Rmeasure 0.130 (2.150) 0.180 (3.013) 0.247 (5.336) 0.175 (3.847) CC 1 / 2 0.994 (0.339) 0.995 (0.332) 0.994 (0.450) 0.994 (0.240)

[0364]

[0365] 10.3 (1.58)c5.6 (1.09)c6.3 (1.05)c4.0 (1.06)cNo. unique 118787 (5716) 131200 (4866) 137661 (6848) 136728 (6757) reflections

[0366] Completeness (%) 98.1 (96.3) 98.6 (74.7) 100.0 (99.9) 98.6 (98.4) Redundancy 3.5 (3.3) 9.1 (4.8) 9.8 (8.8) 5.0 (5.0) No. crystals 1 2 2 1

[0367] Wilson B factor (A) 35.8 39.6 33.7 36.4Refinement

[0368] Resolution (A) 2.05 1.99 1.95 1.94

[0369] No. reflections used 127682 131029 137509 136615

[0370]

[0371] No. atoms, Protein 12824 12857 12848 12874 Ligand / ion 556 506 542 522

[0372] Water 596 509 735 536

[0373] R.m.s. deviations

[0374] Bond lengths (A) 0.009 0.009 0.010 0.008

[0375] Bond angles (°) 1.01 0.97 1.17 1.02

[0376] aSee Figure 2 for nomenclature and chemical formula of inhibitors.

[0377] bRfree was calculated with the 5% of reflections set aside throughout the refinement. The set of reflections for the Rfree calculation were kept the same for all data sets according to those used in the data of the starting model (7TS9 for rnNOS in C222i, 7TS7 for hnNOS in P2₁, and 5UO8 for heNOS in P2₁).

[0378] cThe < 7 / oZ > value in the highest resolution shell calculated by Xtriage and reported in the wwPDB X-ray Structure Validation ReportReference (SI)

[0379] 1. Roman, L. J.; Sheta, E. A.; Martasek, P.; Gross, S. S.; Liu, Q.; Masters, B. S. Highlevel expression of functional rat neuronal nitric oxide synthase in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 8428-8432.

[0380] 2. Li, H.; Shimizu, H.; Flinspach, M.; Jamal, J.; Yang, W.; Xian, M.; Cai, T.; Wen, E. Z.; Jia, Q.; Wang, P. G.; Poulos, T. L. The novel binding mode of N-alkyl-N'-hydroxyguanidine to neuronal nitric oxide synthase provides mechanistic insights into NO biosynthesis. Biochemistry 2002, 41, 13868-13875.

[0381] 3. Li, H.; Jamal, J.; Plaza, C.; Pineda, S. H.; Chreifi, G.; Jing, Q.; Cinelli, M. A.; Silverman, R. B.; Poulos, T. L. Structures of human constitutive nitric oxide synthases. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2014, 70, 2667-2674.

[0382] 4. Do, H. T.; Li, H.; Chreifi, G.; Poulos, T. L.; Silverman, R. B. Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold. J. Med. Chem. 2019, 62, 2690-2707.

[0383] 5. Yung-Chi, C.; Prusoff, W. H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (150) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108.

[0384] 6. Leber, A.; Hemmens, B.; Klosch, B.; Goessler, W.; Raber, G.; Mayer, B.; Schmidt, K. Characterization of recombinant human endothelial nitric-oxide synthase purified from the yeast Pichia pastoris. Z Biol. Chem. 1999, 274, 37658-37664.

[0385] 7. Madhavi Sastry, G.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. AidedMol. Des. 2013, 27, 221-234.

[0386] 8. Jacobson, M. P.; Pincus, D. L.; Rapp, C. S.; Day, T. J.; Honig, B.; Shaw, D. E.; Friesner, R. A. A hierarchical approach to all-atom protein loop prediction. Proteins: Structure, Function, and Bioinformatics 2004, 55, 351-367.

[0387] 9. Lu, C.; Wu, C.; Ghoreishi, D.; Chen, W Wang, L.; Damm, W.; Ross, G. A.; Dahlgren, M. K.; Russell, E.; Von Bargen, C. D. OPLS4: Improving force field accuracy on challenging regimes of chemical space. Journal of chemical theory and computation 2021, 17, 4291-4300.10. Cinelli, M. A.; Reidl, C T.; Li, H.; Chreifi, G.; Poulos, T. L.; Silverman, R. B. First contact: 7-phenyl-2-aminoquinolines, potent and selective neuronal nitric oxide synthase inhibitors that target an isoform-specific aspartate. J. Med. Chem. 2020, 63, 4528-4554.

[0388] 11. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The protein data bank. Nucleic Acids Res. 2000, 28, 235-242.

[0389] 12. Bochevarov, A. D.; Harder, E.; Hughes, T. F.; Greenwood, J. R.; Braden, D. A.; Philipp, D. M.; Rinaldo, D.; Halls, M. D.; Zhang, J.; Friesner, R. A. Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences. Int. J. Quantum Chem 2013, 773, 2110-2142.

[0390] 13. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749.

[0391] 14. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 2006, 49, 6177-6196.

[0392] 15. Bowers, K. J.; Chow, E.; Xu, H.; Dror, R. O.; Eastwood, M. P.; Gregersen, B. A.; Klepeis, J. L.; Kolossvary, I.; Moraes, M. A.; Sacerdoti, F. D. Scalable algorithms for molecular dynamics simulations on commodity clusters. In Proceedings of the 2006 ACM / IEEE Conference on Super computing, 2006; pp 84-es.

Claims

CLAIMSI / We claim:

1. A compound of formula (I), or a salt, hydrate, or solvate thereof,whereinn is 0 or 2;R1is halogen;R2is -(CH2)m-NHRA, halogen, -OH, or -H;R3is -OH, -H, -(CH2)m-NHRA; halogen, or -O-C1-C5-alkyl, wherein the -O-C1-C5-alkyl is optionally substituted with a C3-C6-cycloalkyl;R4is -H or halogen;R5is -H, halogen, or -OH;m is 1 or 2; andRAis H or Ci-C3-alkyl;with the proviso that one and only one of R2and R3is -(CH2)m-NHRA.

2. The compound of claim 1, wherein R1is -F.

3. The compound of any one of claims 1-2, wherein n is 0.

4. The compound of any one of claims 1 -3, wherein R2is -CH2-NH2, -OH, -F, -H, -CH2-CH2- NH2, -CH2-NHMe, or -CH2-CH2-NMe.

5. The compound of claim 4, wherein R2is -CH2-NH2.

6. The compound of any one of claims 1-5, wherein R3is -OH, -F, -O-CHz-cyclopropyl, - CH2-NH2, -H, -CH2-CH2-NH2, -CH2-NHMe, or -CH2-CH2-NMe.

7. The compound of claim 6, wherein R3is -OH.

8. The compound of any one of claims 1-7, wherein R4is -H or -F.

9. The compound of any one of claims 1-8, wherein R5is -H, -F, or -OH.

10. The compound of any one of claims 1-9, wherein R4and R5are both -H.

11. The compound of claim 1, or a salt, hydrate, or solvate thereof, wherein the compound is12. The compound of claim 1, or a salt, hydrate, or solvate thereof, wherein the compound is13. The compound of any one of claims 1-12, wherein the compound is selective for human neuronal NOS (nNOS) over human endothelial NOS (eNOS).

14. The compound of any one of claims 1-13, wherein the compound is selective for human neuronal NOS (nNOS) over human inducible NOS (iNOS).

15. The compound of any one of claims 1-14, wherein the compound has a i value of human nNOS that is less than 100 nM, calculated using the Cheng-Prusoff equation.

16. The compound of any one of claims 1-15, wherein the effective permeability (Pe) for the blood brain barrier of the compound is at least 4.0 x 10'6cm s'1.

17. A salt of the compound of any one of claims 1-16 of formula (I-a).

18. A pharmaceutical composition comprising the compound according to any one of claims 1-16, or a salt, hydrate, or solvate thereof, and a pharmaceutically acceptable excipient, carrier, or diluent.

19. A method for treating a disease or disorder associated with neuronal nitric oxide synthase (nNOS) activity in a subject in need thereof, the method comprising administering an effective amount of the compound of any one of claims 1-16, or a salt, hydrate, or solvate thereof; or the pharmaceutical composition of claim 18 to the subject.

20. The method of claim 19, wherein the disease or disorder is a neurological disease or disorder, a cardiovascular disease or disorder, a cancer, or an inflammatory condition.

21. The method of claim 20, wherein the neurological disease or disorder is Alzheimer's disease (AD), migraine, epilepsy, chronic pain, stroke, autism spectrum disorder, Parkinson's disease (PD), Huntington's disease (HD), or amyotrophic lateral sclerosis (ALS).

22. The method of claim 20, wherein the cardiovascular disease or disorder is hypertension, heart failure, erectile dysfunction, or atherosclerosis.

23. The method of claim 20, wherein the cancer is melanoma, breast cancer, glioma cancer, prostate cancer, or lung cancer.

24. The method of claim 20, wherein the inflammatory condition is arthritis, inflammatory bowel disease, or asthma.